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Abstract
Hypofractionated radiotherapy treatments of the prostate deliver very high doses
to the target volume, whilst attempting to spare healthy surrounding tissue. This
leads to an extremely high dose gradient at the anterior rectal wall. Small geometrical deviations in target localisation may lead to a high dose delivered to the rectal
wall. The aim of this phantom based study was the development and testing of a
system for measurement of anterior rectal wall doses during hypofractionated high
dose radiotherapy treatments of HDR brachytherapy and TomoTherapy R . A Perspex replica transrectal ultrasound probe was utilised within a surrogate rectum, with
clinical treatments delivered to the phantom. MOSkin

TM

detectors were attached to

the probes to measure dose rates to the rectal wall in real–time. A comparison of a
hollow and solid Perspex probe determined if the solid probe increased rectal wall
dose by introducing extra backscatter material. For brachytherapy, similar results
were produced between probes. Dual MOSkin

TM

detectors, employed to improve the

accuracy of measurement over a single detector arrangement, increased agreement
between measured and TPS doses, with all dual detector results demonstrating acceptable agreement (within 5%). For TomoTherapy R , the probe was utilised as a
Perspex surrogate for the Rectafix R . At the anterior rectal wall using single detectors and accounting for acceptable Distance–to–Agreement measurements, 87.5%
of detectors measured dose to within ±5% of the TPS. Dual MOSkin

TM

detectors

further improved results, allowing for acceptable agreement of all detector measurements with the TPS. The dual MOSkin

TM

system, if employed clinically, could help

to detect errors, such as patient shifts or incorrect set–up, in dose delivery for HDR
brachytherapy and Helical TomoTherapy R for the treatment of prostate cancer.
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Chapter 1
Introduction
Prostate cancer is the most common cancer type in Australian men, with one in nine
men developing the disease at some stage in his lifetime [1]. More than 95% of
prostate cancers arise from the epithelial cells of the prostate gland in the form of
prostate adenocarcinoma [2]. The risk of prostate cancer increases with age and
family history of the disease. Other risk factors include race and ethnicity, socio–
economic factors, environmental exposure and diet [2].

Treatment for prostate cancer includes surgery, chemotherapy, hormone therapy, radiation therapy, or a combination of these. Radiation therapy includes options such
as high or low dose rate (HDR or LDR) brachytherapy, or external beam options
such 3D conformal radiation therapy (3DCRT), intensity modulated radiation therapy
(IMRT), volumetric modulated arc therapy (VMAT) and Helical TomoTherapy R
techniques. The types of radiation therapy to be discussed here are HDR brachytherapy and Helical TomoTherapy R . Brachytherapy involves the use of a radiation
source implanted close to the treatment site in the patient, whereas TomoTherapy R
is delivered helically from an external beam.

Radiation dose delivered in the form of brachytherapy has a steep dose gradient outside the target volume as the organs at risk (OARs) in the vicinity of the prostate
are quite close to the treatment field, meaning errors in the set up of a patient for
1

2

Introduction

treatment could be detrimental in terms of patient side effects. Various studies have
aimed to improve the accuracy of brachytherapy treatments through, for example,
positioning methods or dosimetric measurement [3–6]. This study aims to incorporate both these aspects into a method of brachytherapy treatment. The MOSkin

TM

,

a MOSFET based dosimeter, is a silicon detector with a very small sensitive volume and designed to measure doses at air/skin interfaces [3]. These detectors will
be attached to a replica ultrasound probe to test whether this method is suitable for
in–vivo dosimetry in prostate cancer treatment. This method has been tested with
another type of detector, a PTW diode array type 9112, in a previous study [5].

This study then investigates the probes’ potential for TomoTherapy R . The Rectafix R
[7] system has previously been developed to improve positioning and immobilisation
in the treatment of prostate radiation therapy, for proton boosts and hypofractionated
photon treatments [8–10]. This study looks at building upon this technology. By
utilising the probe as a surrogate for the Rectafix R , coupled with MOSkin

TM

detec-

tors; the probe can not only assist in immobilisation, but can ensure the geometric
conditions are the same for improved accuracy in plan delivery and dosimetric measurement in a high dose gradient region. Further accuracy was investigated by the
addition of fiducial markers to the probe in one case.

1.1

Objectives and Overview of this Thesis

Using the same geometry for treatment as for the volume study with the transrectal ultrasound (TRUS) probe; and also measuring the dose in real time; this study
aimed to improve the correspondence between planning and treatment doses. A
replica ultrasound transducer has been developed at the Centre for Medical Radiation
Physics (CMRP), University of Wollongong for use in both prostate brachytherapy
and TomoTherapy R . It is capable of in–vivo measurements of absorbed dose to the
TM

anterior rectal wall using MOSkin

detectors positioned along the anterior edge of

the probe. Two probes were designed and compared: a solid Perspex probe con-
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taining four detectors and a hollow Perspex probe containing four detectors. This
Thesis has two dose verification studies: the HDR brachytherapy study completed
at St. George Cancer Care Centre (SGCCC), St. George Hospital, Kogarah, and the
TomoTherapy R study completed at Liverpool Hospital, Liverpool.
The fundamental objectives of this Thesis are as follows:

1. Design and development of replica ultrasound probes that have the ability to
TM

house MOSkin

detectors.

2. Completion of preliminary measurements for both HDR brachytherapy and
TomoTherapy R studies, such as detector calibration and backscatter comparison, using a CIRS Plastic Water R LR solid water phantom and CIRS IMRT
Head and Torso Freepoint Phantom for brachytherapy and TomoTherapy R
respectively.
3. Determine whether MOSkin

TM

detectors could measure dose to the rectum

within ±5% of the dose calculated by the treatment planning system for HDR
brachytherapy and TomoTherapy R .
4. Comparison of replica probes for HDR brachytherapy and TomoTherapy R
using a gelatine phantom and IMRT Head and Torso Freepoint Phantom respectively. Comparison of a solid Perspex probe and a hollow Perspex probe
to determine whether the solid probe increased dose to the rectal wall due to
the added backscatter material.

Chapter 2
Literature Review
2.1

Prostate Cancer and Treatment Options

The prostate is an organ made up of glandular, fibrous, and muscular elements. It
encapsulates the beginning of the urethra, and is situated inferiorly to the base of
the bladder. Attached to the posterosuperior portion of the prostate gland are the
seminal vesicles and vas deferens. The prostate gland consists of four zones: the
central, transition, fibromuscular, and the largest; the peripheral zone [2, 11].

75% of prostate carcinomas develop in this peripheral zone, although benign
prostatic hyperplasia (BPH) usually originates in the transition zone. Prostate cancer
can extend not only into the other zones, but also into the seminal vesicles, rectum,
and bladder neck. Metastases to the lymph nodes and other regions of the body are
dependent on the size and degree of differentiation of the primary tumour [2, 11].

Tests such as the Prostate Specific Antigen (PSA) test are carried out to assist
in diagnosing and staging the cancer [2, 12]. PSA is a type of protein and its presence in the bloodstream may indicate that a tumour (whether benign or malignant)
has affected the membrane of the prostate gland, allowing PSA to pass into the
bloodstream [13]. A PSA of >0.4 µg/L is considered a risk factor, however it
may be higher due to other factors such as surgery or androgen deprivation therapy
4
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(ADT) [2].

The staging and Gleason score are established, which determine the treatment
options and outcome for the patient. Clinical staging is based on PSA, digital
rectal examination (DRE) findings, and imaging, whereas pathologic staging
is based on the biopsy results and the American Joint Committee on Cancer
Guidelines 2007. These guidelines grade the tumour with the letters: T N M . T
is the tumour extent and can range from T1–T4. N represents the lymph node
involvement and can be NX (no sample available), N0 (no positive nodes) or
N1 (nodal involvement). M indicates whether there is metastatic disease present
by either M0 (no metastases) or M1 (metastases) [2]. The Gleason score is a
numbered grading system based on the histopathology of the prostate cancer and
is used as an indicator of patient outcome [14]. Gleason scores can range between
2 and 10; the higher the score, the more aggressive and metastatic the cancer [11,13].

Treatment options are decided based on the stage of the disease, although there is
still no consensus on the best option to treat prostate cancer according to Simmons,
Berglund and Jones (2011) [13]. For small, slow–growing tumours (i.e. T1a), observation is sometimes preferred over treatment. It is also an option for elderly patients
(if life expectancy is less than 10 years) [11, 13] for whom treatment may decrease
quality of life rather than improve upon it. Observation generally includes DRE and
PSA testing every 6–12 months [13]. If the tumour is beyond the observation stage,
treatment options include surgery, chemotherapy, hormone therapy and radiation
therapy, or a combination of various treatment options. Other treatments for prostate
cancer that are not yet commonly employed, or are still in the development stage, are
cryotherapy, high–intensity focused ultrasound, orchiectomy, and focal ablation [13].

Radical prostatectomy is usually the treatment option used for lower stage, localised tumours, such as T1 or T2. A minimum life expectancy of 10 years is a
requirement for surgery [11]. This type of surgery aims to remove the prostate
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gland and seminal vesicles, as well as sometimes including the pelvic lymph nodes
for intermediate– to high–risk cases [13, 15]. Side effects of radical prostatectomy
include incontinence and sexual dysfunction, however, the aim is obviously to
reduce or avoid these effects [15]. After radical prostatectomy, recurrence rates at
5 years are very minimal for low–risk patients, at only about 6%. Patients with
positive surgical margins generally undergo external beam radiation therapy (EBRT)
within 3–6 months of their surgery to kill residual tumour cells [13].

Chemotherapy is the administration of cytotoxic drugs to a patient for the systemic treatment of cancer. It can be delivered via injection (intravenous, intraarterial
or intrathecal), orally or for some types of cancer, by cavity insertion. The drugs
are aimed at destroying tumour cells by affecting them at a certain stage of the cell
cycle [11]. Hormone therapy, or ADT, involves the treatment of prostate cancer with
hormones such as leutinizing hormone–releasing hormone agonist or antagonist
to reduce the production of testosterone [11, 13]. It is not used as a monotherapy
for prostate cancer due to its ineffectiveness on its own, but rather as an adjuvant
therapy to radical prostatectomy or radiation therapy for high–risk patients [13, 16].

Radiation therapy can be either external beam or brachytherapy; both of which are
described in the following sections.

2.2

Brachytherapy

Brachytherapy to the prostate is an invasive procedure involving sources of radiation being inserted into the patient to treat the affected tissue. This type of
treatment effectively spares normal tissue whilst treating the tumour due to the
steep dose gradient.

Prostate brachytherapy is an interstitial form of therapy.

HDR brachytherapy is in the form of removable implants, which involve multiple
catheters being inserted into the patient and an afterloading technique being used
to send the source down each catheter. These catheters are inserted for only a
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couple of, or a few days, whilst treatment is being carried out, and then they are
removed [17], although most HDR insertions are for a few hours from time of
implantation to the time of treatment [18]. The source travels down the catheter
in ‘steps’, staying at each step for a predetermined dwell time [19]. This differs
from LDR where the radiation sources are permanent, with a continuous treatment
over the lifetime of the source. The dose rate for HDR can be up to 5 Gy/minute
in tissue at a distance of 5 mm from the source [17]. LDR brachytherapy uses
permanent implants (radioactive seeds) which are inserted into the tumour volume to
deliver the dose over a few months. The dose rate on average is 10 cGy/hour [17,19].

HDR uses a medium energy source but with a high activity as the dose needs
to be delivered over a shorter amount of time than in LDR. LDR uses a low energy,
low activity source as it is delivered over a few months. The purpose of using a low
energy is to keep the dose to surrounding organs low and in the case of LDR; to keep
the dose to the general public low. The patient emits a small amount of radiation
until the source decays in LDR but in HDR the patient is not radioactive after the
source has been removed [17]. HDR commonly utilises Iridium–192 (192 I), which
has a half–life of 73.83 days. It decays to an excited state of Platinum (192 Pt) by
β - , and to an excited state of Osmium (192 Os) by electron capture. De–excitation
occurs by the emission of gamma rays with an average energy of approximately 370
keV [20].

The α/β ratio is a parameter of the linear–quadradic (LQ) formalism when
determining the survival curve of early– and late–responding tissues, and hence
determining the sensitivity of these different tissue types to fractionation. Tissues
that are late–responding have a low α/β ratio and have been shown to be spared
more by fractionation, whilst fractionation has been shown to have a higher cell kill
in early–responding tissues, such as tumours. However, prostate cancer is believed
to have a low α/β ratio (between 1.5 and 3), and cell kill has been shown to increase
when using larger fraction sizes for low α/β ratios [21]. The radiobiological effect is
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different between LDR and HDR [21]. LDR reduces the effect on late–responding
tissues and gives the normal tissue time to repair whilst damaging cells with a higher
α/β ratio, which are early–responding. HDR has a greater biological effect than
LDR on tissues with a lower α/β ratio [19]. The trend is toward HDR treatments as
these treatments are hypofractionated and each fraction size is larger than normal
fractionation regimens, which would be more beneficial for prostate cancers if they
do have a low α/β ratio. However, it is still not known exactly what the α/β ratio for
prostate cancer is [19, 21].

The aim of treatment planning in HDR brachytherapy, as reported by Simmons, Berglund and Jones (2011), is to cover at least 90% of the prostate with 100%
of the radiation dose [13]. The dose fractionation regimen at St. George Cancer Care
Centre (SGCCC), St. George Hospital in Kogarah, New South Wales, where this
project took place, is as follows: HDR brachytherapy delivers 18 Gy in 2 fractions
(1 fraction per day) where the patient stays at the hospital as an in–patient overnight.
4–6 fractions are also commonly used at other centres [17]. For LDR, once the seeds
have been inserted (and after recovery from the procedure) the patient is free to go
home. LDR is used as a monotherapy whereas HDR is used as a boost for external
beam treatment, which is an added 46 Gy in 23 fractions to the overall treatment.

When treating any area of the body with radiation therapy, the OARs must be
taken into account when planning a treatment to minimise each organ dose as
much as possible. Dose optimisation on the computer planning program allows
these organs to be avoided as much as possible [19]. However, regardless of how
much the dose to these organs is minimised, there is still a chance of side effects.
Side effects of prostate brachytherapy include urinary incontinence, urgency and
frequency, dysuria, rectal bleeding, diarrhoea, proctitis and erectile dysfunction [2].
Late rectal toxicity resulting from irradiating the rectal wall can impact quite
negatively on a patient’s life [22, 23]. Measuring the dose to the anterior rectal wall
allows monitoring of whether the planned dose is actually being delivered to that site.
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HDR brachytherapy has been shown to produce good outcomes for the treatment of prostate adenocarcinoma. The results of a study by Brenner and colleagues
in 2002 demonstrate strong evidence that α/β values for prostate tumour control
are low, meaning these tumours have a high sensitivity to fractionation. This is
more typical of late–responding normal tissue, and not so common in tumours [21].
Therefore, large dose fractions are ideal for treating prostate adenocarcinomas,
which HDR brachytherapy delivers.

In a recent study [24], data was analysed for the period of 2003–2009, with
197 patients treated with HDR brachytherapy for prostate adenocarcinoma. Only
patients with T1 to T3b tumours and a PSA of less than 40 µg/L were included in
the study. 30 patients were treated with 34 Gy in 3 fractions, 25 with 36 Gy in 3
fractions, 109 patients with 31.5 Gy in 3 fractions and 33 patients were given 26
Gy in 2 fractions. No significant difference in extent and severity of either early
or late rectal or urinary radiation effects were observed for the variations in dose
fractionation. For the high–risk patients, 91% were free of biochemical relapse after
3 years, and 99% were free for the intermediate–risk group. At 4 years, 87% were
free from relapse in the high-risk group and 95% for the intermediate–risk. HDR
brachytherapy has been shown to have a lower rate of incontinence as a side effect,
and is also a less expensive treatment option than radical prostatectomy [13].

At SGCCC, the eligibility criteria to receive HDR brachytherapy to the prostate
includes intermediate– to high–risk prostate cancer patients with no evidence of
nodal or distant metastases. High risk patients must have only one of either a PSA
of ≥20 µg/L or a Gleason score of ≥8 or be stage T3a. Patients must have had
no trans–urethral resection of the prostate (TURP) and have a life expectancy of 5
years or more [25]. A Nucletron HDR unit is utilised to treat patients, with planning
completed on an Oncentra R Brachy Treatment Planning System.
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Currently, brachytherapy TPS are based on the AAPM TG–43 formalism,
which will be described in Section 2.5. This formalism is based on the superposition
of single–source dose distributions in a liquid water phantom. A fixed volume is
utilised for radiation scattering. Brachytherapy TPS currently do not account for
heterogeneity in tissue and also in applicators, and changed scattering conditions
based on organ/body contour. Hence, uncertainties lie in its limitations for patient
dose calculation. New model–based dose calculation algorithms (MBDCAs) are
being developed, such as those based on Monte Carlo or collapsed cone. Fortunately,
for prostate treatment, prostates are surrounded by an adequate depth of tissue and
hence, are not as affected by scattering conditions as are some other treatment
areas.

TG–186 recommended that current TG–43 practices be implemented

alongside MBDCAs to assess the impact of utilising these algorithms in clinical
practice [26, 27].

2.3

External Beam Radiation Therapy

EBRT is a non–invasive treatment that uses high energy x–rays (usually 6–18 MV)
to deliver dose to the patient, mostly commonly with a linear accelerator. Previously,
a ‘four–field box’ technique was used to deliver treatment to the prostate, seminal
vesicles and lymph nodes, with generally 45 Gy prescribed to the whole treatment
field and the prostate itself boosted to 70 Gy or more. Nowadays, 3DCRT and
IMRT are the techniques usually employed. Other techniques employed are VMAT,
TomoTherapy R and Stereotactic Body Radiation Therapy (SBRT). 3DCRT uses
multileaf collimators (MLCs) to conform the treatment field to the prostate and
other affected areas. A simulation CT scan is taken and 3D planning is utilised.
IMRT utilises many beam segments to modulate the intensity of the beam within
each treatment field. Inverse treatment planning is used to achieve optimisation
by the user providing dose objectives and then the planning program calculates a
dose distribution from these objectives. IMRT treatments generally deliver doses
of 75–85 Gy over 30–36 days [13, 28]. Static and dynamic options for MLCs are

Literature Review

11

available in IMRT. Static IMRT means the leaves are stationary during dose delivery,
and dynamic IMRT means the leaves are moving. Dynamic IMRT has been found
to require 15–20% more monitor units (MUs) and 15% more time than static IMRT;
increasing the risk of secondary malignancies from radiation exposure [29–31].
However dynamic IMRT, with its continuous MLC motion; allows the intensity that
is actually delivered to resemble the optimal fluence of the plan more closely [29].

IMRT has been shown to reduce the dose to critical structures in comparison
to 3DCRT, whilst being able to escalate the target dose [32–34]. Advantages of
3DCRT include that this technique requires less MUs than static IMRT, depending on
the energy (3.5–4.9% times less), and hence also less than dynamic IMRT [29, 35].
In a comparison between IMRT and 3DCRT to the prostate, mean doses to the
prostate were similar at 75.10 Gy and 75.40 Gy respectively, with seminal vesicle
mean doses at 75.11 Gy and 75.02 Gy respectively. It was found that 3DCRT
delivered significantly higher doses to the rectum, with 66% of the rectum receiving
10.18 Gy more dose, 50% receiving 6.64 Gy more and 33% receiving 3.55 Gy more
dose than IMRT. The same percentage volumes of the upper rectum received even
higher doses [32]. Michalski et al. (2011) reported the findings of a Phase III RTOG
trial investigating the rectal toxicities of 748 patient receiving prostate 3DCRT and
IMRT. The median V65, V70, and V75 of the rectum and were found to be reduced
for IMRT: 27.4%, 21.7%, and 15.8% respectively for 3DCRT in comparison to
23.0%, 18.2%, and 13.0% respectively for IMRT [36].

TomoTherapy R is another option utilised to deliver EBRT. TomoTherapy R
involves the use of a rotating narrow fan beam to deliver dose to the patient. Binary
MLCs (i.e. either in an open or closed state operating in the superior/inferior
direction of the patient) form a 1D profile that constantly changes; combining the
1D profile with beam rotation, intensity modulation in 2D is produced. The rotation
becomes a helical rotation due to the movement of the couch through the bore of
the gantry. However, TomoTherapy R can also deliver a treatment field with a
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fixed couch position. The helical delivery method is advantageous as it does not
allow any overlapping of the fields at the junctions, which can lead to overdosing or
underdosing. Parameters that affect dose modulation, resolution and treatment times
are collimator width, pitch (i.e. couch movement per rotation) and the modulation
factor (i.e. the ratio of the maximum time a certain leaf is open to the mean time
that all leaves are open) [17, 37]. TomoTherapy R also has the ability to take CT
images of the patient before each treatment to verify positioning [38–41]. Other
advantages of TomoTherapy R include its capability of generating very complex,
highly intensity modulated dose distributions due to its greater number of degrees
of freedom, and that it has the ability to treat large volumes in a single treatment
delivery [42].

VMAT, another option for EBRT, is a type of IMRT that utilises modulated
fields to deliver a conformal dose in one or more rotations of the gantry. The
modulated field is achieved by varying dose rate, MLC aperture and orientation,
and gantry speed, with the beam switched on continuously for efficient treatment
delivery [43–45].

There are several disadvantages of EBRT, which include the length of treatments (i.e. daily treatments over many weeks) and the long–term side effects.
These effects include frequency and urgency of urination, nocturia, hemorrhagic
cystitis, rectal bleeding and pain, and of course, risk of a secondary malignancy.
EBRT modalities also provide an expensive treatment option [13], due to the
‘activity–based’ calculation of treatment costs (from clinical assessment to follow–
up), with the model primarily based on factors such as equipment/materials,
buildings/facilities and staffing [46].

A study by Tsai et al.

(2011) compared step–and–shoot IMRT, helical

TomoTherapy R and VMAT, in terms of treatment and dosimetry for prostate
cancer. Three plans for each treatment delivery method were completed for each
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of twelve patients. All three plan types met the aims for target volume dosimetry
and the constraints for OARs.

The average maximum planning target volume

(PTV) doses for all three plan types was similar, and PTV coverage was also
similar, however TomoTherapy R had the best PTV conformity. The percentage
volume of the rectum receiving 65 Gy and 40 Gy (i.e. the dose volume levels for
the rectum [47, 48]) was 9.1% and 24.8% for TomoTherapy R , 12.4% and 30.8%
for VMAT, and 14.7% and 35.5% for step-and–shoot IMRT. It can be seen that
TomoTherapy R plans had better sparing of the rectum at 65 and 40 Gy [49].

The study found that the mean required MUs were 309.7 for VMAT, 336.1
for step–and–shoot IMRT, and the highest for TomoTherapy R at 3368.

The

advantage of lower MUs is a lesser scattered dose to the body. The treatment
time required was lowest for VMAT at 2.6 minutes, with step–and–shoot IMRT
and TomoTherapy R taking 3.8 minutes [49]. Less treatment time is an advantage in terms of potentially reducing intrafractional movement [50] and reducing
out–of–field, scattered and leakage doses [51].

TomoTherapy R was shown

to be superior in some dosimetric aspects, although it needed more MUs and
time to deliver.

The authors recognise that their study was limited in that it

had a small patient number [49]. Aspects of TomoTherapy R contributing to the
longer treatment time are the number of rotations needed and the slice thickness [51].

Helical TomoTherapy R can have treatment times longer than treatment times
using a conventional linear accelerator [51]. When compared to RapidArc (Varian’s
implementation of VMAT), a typical prostate treatment using TomoTherapy R
requires a treatment time of 4–7 minutes, whereas RapidArc can take about 1.5
minutes. Although this is for relatively simple cases only [42, 52]. However, despite
the longer treatment times, the shielding is maximised in the delivery system of the
TomoTherapy R machine to minimise radiation leakage [51].

A study by Ramsey et al.

(2006) aimed to measure the out–of–field doses,
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in–air scatter and leakage doses using TomoTherapy R . The results showed that
peripheral doses were equal to or less than those found previously for IMRT
treatments using conventional linear accelerators; with peripheral dose dropping
to 0.4% of the prescribed dose at 20 cm. At distances of 60 cm or more from the
machine’s isocenter, leakage dose made up 94% of the in–air dose. Peripheral doses
were lower than expected, and these lower doses were due not only to the increased
shielding, but also due to the fact that there is no flattening filter in TomoTherapy R
units, unlike in conventional accelerators. As well as this, the beamlets used are
narrow, contributing to the reason for these lower doses [51].

The type of EBRT to be used in this study is a TomoTherapy R boost.

Hy-

pofractionation such as this may be advantageous in the treatment of prostate cancer
due to the estimated low α/β ratio of prostate cancer [53]. TomoTherapy R is
a type of SBRT. SBRT can deliver this hypofractionated dose with examples of
prescriptions varying from 35 Gy in 7 fractions to boosts of 19 Gy in 2 fractions.
SBRT has been shown to produce low rates of acute low urinary and rectal toxicity
(Grade II) [53–55]. Jabbari et al. (2011) completed a study with twenty patients
treated with prostate SBRT as a monotherapy, with a prescription of 9.5 Gy in 4
fractions. Another eighteen patients were given a boost with SBRT of 9.5 Gy in
2 fractions, after their treatment with EBRT and ADT. They found that 42% had
acute Grade II gastrourinary and 11% of patients had acute Grade II gastrointestinal
toxicity.

There was no Grade III acute toxicity found, however, two patients

experienced late Grade III gastrourinary toxicity [54].

In 2010, in a study by Katz et al., seventy–three patients were treated with 45
Gy EBRT along with an SBRT boost.

The boost prescription varied between

patient groups, and the various presciptions were: 18 Gy in 3 fractions, 19.5 Gy
in 3 fractions, and 21 Gy in 3 fractions. It was found that less than 7% of patients
experienced Grade II acute urinary and rectal toxicity. Only one patient experienced
Grade III late toxicity [53]. Oermann et al. in 2010 published a study using
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CyberKnife R to deliver a SBRT boost of 19.5 Gy in 3 fractions along with an
IMRT prescription of 50.4 Gy in 28 fractions to twenty–four patients, some also
being treated with ADT. 13% of patients experienced Grade II gastrourinary toxicity
and 4% of patients experienced Grade II gastrointestinal toxicity, with no Grade III
observed [55].

In comparison to this, HDR brachytherapy has been shown to produce acute
Grade II gastrourinary toxicity rates in the range of 5.5–22.5%, and acute Grade II
gastrointestinal toxicity in the range 3.9–7.0%. Grade III gastrourinary toxicity was
found to be experienced by 1.8–3.9% of patients [55–59].

The TomoTherapy R Hi–Art R treatment planning system employed in this
study utilises a convolution/superposition algorithm for dose calculation, based
on the collapsed–cone method. Algorithms developed to save on calculation time
can introduce distortions in dose distributions. This is particularly an issue in
low density media for small fields, including IMRT small field superposition [60].
Superposition/convolution algorithms were found by Dogan et al. (2009) to agree
with Monte Carlo calculations (the current gold standard in dose calculation
algorithms) to within 2% for prostate IMRT [61]. Another study by Francescon et
al. (2003) compared a collapsed–cone algorithm with Monte Carlo calculations for
step–andshoot prostate IMRT and found a difference of 2.1% between the two algorithms at isocentre. More complex IMRT plans with more heterogeneous tissues,
such as the head and neck region, show a larger discrepancy than for IMRT prostate
plans. A 2.9% difference was found at isocentre for the head and neck plans. Larger
discrepancies were observed on the dose–volume histogram (DVH); with a deviation
of <6% for doses less than 85% of the prescribed dose, and much larger dose
discrepancies for doses above the 85% due to the small segment contribution [62].
Superposition/convolution algorithms have uncertainty in prediction of fluence, as
well as photon transmission through the patient and through MLCs [61].
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Quality Assurance and Immobilisation
Prostate Radiation Therapy
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Prostatic motion may occur between fractions (interfraction) and during fractions
(intrafraction). Intrafraction motion is unpredictable and can include both sudden
or slow motion [63–65]. To ensure accurate treatment delivery to the prostate,
equipment for the immobiliation of the prostate and patient is utilised, with quality
assurance (QA) procedures established. QA reduces errors from the planning process of a patient’s treatment to the actual treatment itself, and the data gathered from
QA tests enables a comparison of results between radiation oncology departments
for clinical trials, to further improve treatments [17].

Problems that arise with prostate brachytherapy are movement of catheter [18], seed
and prostate, and also changes in the tissue due to oedema arising from catheter
insertion. Human error contributes to this. Whitaker et al. (2011) found the median
catheter movement to be 7.5 mm, with the range of movement being between
−2.9–23.9 mm [18]. Currently, in both HDR and LDR brachytherapy, TRUS is used
for guidance of catheter/seed insertion and and C–arm fluroscopy is used to provide
visualisation of the implants [66]. TRUS allows the insertion of implants through
the perineum into the prostate, guided by a template according to what was planned
in the case of LDR. For HDR, the plan is completed after catheter insertion and after
a CT scan is completed [67].

Although TRUS visualises the soft tissue well (but is not good for visualisation of seed positions), and fluroscopy visualises the implants, they are not used
real–time during treatment. Another disadvantage of fluroscopy is the extra dose
given to the patient and exposure to the operators. It is also difficult to relate source
positions to the prostate itself using the conventional methods of treatment planning [66,68]. Another issue is the relatively long source dwell time for acquisition of
images to resolve source position, again, increasing patient dose. In–vivo dosimetry
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detectors addresses these issues by allowing real–time measurement

of dose to the patient without further increasing patient dose.

Endorectal balloons (ERBs) are inflated with air after rectal insertion; displacing the anterior rectal wall anteriorly. ERBs increase the distance between the
prostate and the posterior rectal wall [9, 69, 70]. Hardcastle et al. (2010) employed
the use of ERBs to immobilise the prostate and also move as much of the rectal
volume as possible out of the high dose region [3]. Spacer gels increase the distance
between the prostate and rectal wall and hence reduce rectal wall dose as they
are injected into the perirectal space (between prostate and anterior rectal wall).
Spacer gels are advantageous as they only require one injection to last the entire
treatment [9, 71, 72]. Alternatively, an ultrasound probe replica has been trialled to
replicate the geometrical conditions between simulation and treatment by Seymour
et al. in 2011 [5]. A new device called the Rectafix R [7] has been introduced, as
reported by two studies: Isacsson et al. (2010) and Nilsson et al. (2014) [8, 9].
A comparison has been made in Table 2.1 between ERBs, spacer gels and the
Rectafix R device in terms of dose–volume reduction and set–up accuracy. It can
be seen that due to the rigidity of the Rectafix R , dose–volumes of the rectum were
decreased, and in comparison to the ERBs and spacer gels; it has an increased set–up
accuracy.

Results: Dose–Volume Reduction

Results: Set-up Accuracy

(2014) created 10

Nilsson et al. (2014) found that rectal

Mean discrepancy between retractor

VMAT plans for patients with and

wall volume was reduced to 0 cm3 for

markers on planning CT scan and

without Rectafix R device. Prescrip-

all dose–volumes except for V32.6Gy ,

treatment images = 0.4 mm [8].

tion used was 42.7 Gy in 7 fractions

although this was only 0.2 cm3 [9].

and dose–volume values of V40.1Gy ,

Isacsson et al. (2010) reported a 67%

V38.3Gy , V36.5Gy and V32.6Gy were

reduction in V70Gy and an average of

evaluated [9]. Isacsson et al. (2010)

5% reduction in maximum dose to

created treatment plans (both with

rectal wall with retraction of rectal

and without Rectafix R ) for 9 patients

wall [8].

Device
Rectafix R

Nilsson et al.
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with a prescription of 20 Gy in 4 fractions for proton boost combined with
50 Gy in 25 fractions of photon beam
treatment. V70Gy was compared between the two cases [8].
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Noyes et al. (2012) utilised 20 mL

For rectal dose above 35 Gy, Noyes et

Noyes et al.

of human collagen as a spacer, with

al. (2012) reported a mean reduction

it was difficult to attain the correct

an IMRT treatment plan comparison

in anterior rectal wall dose of 50%.

consistency (clumping could occur)

completed with and without the col-

V40Gy was reduced to 7–15% with

of human collagen [71]. Hyaluronic

lagen injected. The prescription was

collagen present, when compared to

acid (naturally–occurring polysaccha-

75.6 Gy in 42 fractions for 11 patients.

20–25% with no collagen present.

ride) appears to degrade within a few

A mean separation of 12.7 mm was

V60Gy was reduced to be less than 1%

weeks after exposure to radiation [71,

achieved between prostate and ante-

[71]. Wilder et al. (2010) reported

73].

rior rectal wall [71].

Wilder et al.

a V60Gy of approximately 12% with

hence may not distribute as evenly

(2010) injected 9 mL of cross–linked

gel, and 33% without gel. A V70Gy of

as some other synthetic agents, such

hyaluronan gel as a spacer gel in 10

approximately 4% with gel, and 25%

as polyethylene-glycol (PEG) [71].

patients for HDR brachytherapy (pre-

without gel was reported. A mean rec-

Wilder et al. (2010) reported thick-

scription: 2.2 Gy in 4 fractions) com-

tal dose of 73 cGy was measured with

ness of hyaluronan gel in the anterior–

bined with IMRT (prescription: 50.4

gel present, and 106 cGy with no gel

posterior direction to be 13±3 mm at

Gy in 28 fractions).

present [72].

beginning of treatment and 10±4 mm

A separation

range of 8–18 mm was achieved [72].

(2012) reported that
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It may be more viscous and

at the end [72].
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Patel et al. (2003) completed treat-

Patel et al. (2003) reported that the

Patel et al.

(2003) found mean

Balloon

ment plans for 5 patients with and

average over all the conditions was

standard deviations in ERB move-

(ERB)

without an ERB inserted for both a

that the rectal volume receiving 65 Gy

ment of 2.6 mm, 3.1 mm and 1.0

6 field 3DCRT and 7 coplanar field

or more was reduced by 39%. The
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IMRT plan with ERB inserted was
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out inclusion of seminal vesicles. 76

found spare the rectal volume most
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Gy in 38 fractions was prescribed.

effectively at of all possible condi-
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ated. Smeenk et al. (2011) completed

anal wall volumes with and without

of patients and hence recommended

a planning study on the use of ERB

ERB were not significantly different.

daily ERB positioning verification

in post–prostatectomy IMRT and their

However, rectal wall volumes were

[70].

affect on anorectal doses. 70 Gy in 35

reduced by: 4% for V20Gy , 8% for

fractions was delivered to 20 patients,

V30Gy , 5% for V40Gy , 2% for V50Gy

and planning scans were completed

and 3% for V70Gy . V60Gy remained
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unchanged [74].

Miralbell et al.
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: Comparison between ERBs, spacer gels and Rectafix R in
terms of dose–volume reduction and set–up accuracy.
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Figure 2.1 Diagram of the Rectafix R inserted into a patient, moving in the posterior direction.

In terms of immobilising a patient specifically for EBRT, equipment such as knee fix
and ankle stocks are used, along with tattoos to align the patient to room lasers for
reproducibile positioning [11]. Imaging devices such as on–board imaging (OBI) or
cone–beam CT (CBRT) are used to produce images that are then aligned to boney
anatomy, soft tissue, or fiducial markers such as gold seeds implanted in the prostate,
to improve patient positioning.

The Rectafix R system is a new type of positioning equipment to be used in
the treatment of prostate radiation therapy. Previously, it has been successfully used
in proton therapy boosts and hypofractionated photon regimens to treat prostate
cancer [8–10]. The Rectafix R consists of a rod that is inserted into the rectum and
then is locked onto a vertical column for immobilisation. This column is attached
to a baseplate and a leg support is also attached to this plate for further stabilisation
of the patient. The shape of the rod is tilted in the posterior direction and once it
is inside the rectum, it is pulled down posteriorly to move the rectum away from
the prostate by approximately 20–25 mm. This reduces the dose received by the
rectal wall, which reduces side effects that would normally result from rectal wall
irradiation [7].
Isacsson et al. (2010) completed a study comparing the dose to the rectum in
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radiation therapy treatment plans using either rectal retraction or no retraction with
a Perspex rod. Both plans included a proton boost treatment of 20 Gy in 5 Gy
fractions that was delivered to the prostate over four consecutive days, and then
50 Gy was delivered in 2 Gy fractions using x–rays over five days per week of
the treatment period. A three–field technique was used for the x–ray treatment.
The rectal retractor was 1.5 cm in diameter and its position was able to be verified
on the both the planning CT scan and x–ray images (used for image guidance
during treatment) by three radiopaque markers. The retractor was able to reduce
interfractional motion of the rectum as well as move the rectal volume out of the
treatment field. The results showed that when rectal retraction was used, dose to the
rectum was significantly reduced (average dose reduction of 5%). This was achieved
by the volume receiving 70 Gy in 2 Gy fractions being reduced by a range of 5–96%
(average of 67%). A mean discrepancy of 0.4 mm was found between the retractor
markers on the planning CT scan and images taken during treatment [8]. Nilsson
et al. (2014) compared two VMAT plans for each of ten patients being treated for
prostate adenocarcinoma, one with the rectum retracted using a Perspex rod and one
without rectal retraction. The plans had a prescription of 42.7 Gy in 7 fractions.
The results of the study by Nilsson et al. demonstrated that the plan that utilised
rectal retraction reduced the dose to various volumes of the rectum, as can be seen
in Table 2.1 [9].

The QA of patient positioning and prostate immobilisation has been discussed,
however, QA in terms of dose verification is completed via in–vivo dosimetry. This
will be covered in the following section.

2.5

In–Vivo Dosimetry

In–vivo dosimetry is a method of monitoring the actual dose delivered to the patient
rather than the planned dose, and can be used as another safety precaution in
treatment delivery. A dosimeter is placed on or inside the patient where the dose
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measurement is needed [75]. According to the ICRU report 24 (1976), an ultimate
check of the actual delivered dose can only be performed through in–vivo dosimetry [6,76,77]. The main examples of dosimeters used in–vivo are thermoluminescent
dosimeters (TLDs), silicon diodes, radiochromic film, MOSFETs and scintillation
detectors [75, 78, 79]. In–vivo dosimetry for external beam radiation therapy takes
into account the various sensitivity factors that affect a dose reading, as well as
calibration factors being calculated [80]. Dependence of the detector on energy,
angle, temperature, dose rate, field size and SSD are taken into account [3, 75, 81].

To perform in–vivo dosimetry measurements in brachytherapy, a number of
factors have to be known and taken into account such as air kerma strength or dose
rate factors. Task Group 43 (TG–43) of the American Association of Physicists
in Medicine (AAPM) put forward a formalism, which allows these factors to be
accounted for in dose calculation. The formalism uses measured data of dose
distributions to allow dose to be approximately calculated around an interstitial
source in two dimensions in a water-equivalent medium [20, 82].

The general formalism for the 2D case is described by:

Ḋ(r, θ) = SK Λ

GL (r, θ)
gL (r)F (r, θ)
GL (r0 , θ0 )

(2.1)

where

• r (cm) is the distance between the source centre and a point–of–interest
• θ (◦ ) is the angle between r and the longitudinal axis of the source
• Ḋ(r, θ) (cGy/h) is the dose rate calculated at the point–of–interest
• SK is the air kerma strength and is measured in U (where 1 U = 1 µGym2 h−1 )
• Λ (cGyh−1 U−1 ) is the dose rate constant
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• GL (r, θ) is the geometry factor
• gL (r) is the radial dose function
• F (r, θ) is defined as the anisotropy function
• r0 and θ0 refer to the reference point (where r0 is the reference distance of 1
cm and θ0 is the polar angle between the line extending to the point–of–interest
and the line along the longitudinal axis of the source)
• The subscript, L, implies a line source was used for the geometry function
[20, 82].

2.6

Semiconductor Physics

This project utilises a type of semiconductor detector. Silicon (Si) semiconductors
can be either n– or p–type. N–type Si semiconductors are doped with impurities of a
donor element. The donor contains a free electron as it is a pentavalent element, and
hence its majority carriers are electrons and minority carriers are positive charges
(or ‘holes’). P–type Si semiconductors are instead doped with a trivalent element
meaning it accepts an electron. It therefore has the opposite majority and minority
carriers to n-type semiconductors [75].

When an n– and p– type semiconductor join, a p–n junction is created.

By

applying a reverse bias across the junction, a depletion layer with a thickness
ranging from approximately 10 µm to 5 mm is formed by the majority carriers
diffusing across this junction to the opposite side. A potential is then created,
resulting in an electric field [75, 83].

When ionising radiation is introduced, electron–hole pairs are created and
these carriers can then diffuse across the depletion layer and the charges can be
collected and measured. The charges collected are proportional to the deposited
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energy from the ionisations. This is linear energy transfer (LET)–independent for
lighter particles such as the electron, which is the particle considered in the energy
ranges of concern for this project. Indirect recombination can be used to determine
the charges that are actually the result of the ionising radiation, and which charges
are from the leakage current from any offset voltage of the electrometer [75, 83].

As reported by Rosenfeld (2005), semiconductor detectors have a much higher
sensitivity than ionisation chambers of the same energy used and they have good
mechanical rigidity and energy resolution. However, a few problems arise in their
use. Long–term irradiation effects include the reducing of the diffusion length of the
carriers and hence the sensitivity of the detector is reduced. A change in temperature
can affect the recombination of electrons and holes and the diode response [83, 84].

2.7

Types of Radiation Detectors

Types of radiation detectors used in dosimetry are diode, diamond and MOSFET
detectors, TLDs, fibre optic dosimeters, ionisation chambers and radiochromic film.
Lambert et al. (2007) compared four different detectors for their dependence on
depth dose, angle and temperature for use in in–vivo dosimetry in HDR brachytherapy [85]. The MOSFET detector, TLD, diamond detector and BrachyFOD detector
(fibre optic dosimeter) were compared. Temperature dependence was found to
be less than 3% for the MOSFET, diamond detector and BrachyFOD. However,
the temperature dependence for the TLD could not be tested as TLDs cannot be
read out in real time. The TLD showed potentially large errors in measurement
(approximately 4%) and its use is limited in in–vivo brachytherapy due to this
reason. The sensitivity response of the LiF chips of the TLDs have a depth dose
dependence, causing a 33% variation in response over an increasing distance from
the source when compared to the dose calculated by the treatment planning system
(TPS). The angular response was not reported due to the ability for a spherically
symmetric TLD to be made [85]. According to Rosenfeld (2002), the over layer of
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a TLD is too thick to be able to obtain measurements at a depth suitable for dose
measurement of the rectal wall in prostate brachytherapy [86].

The diamond detector is prevented from being a good method of measurement for in–vivo brachytherapy because it is large and rigid, which is unfortunate as
it is closer to tissue equivalence than other semiconductor detectors [84,85]. Lambert
et al. reported that this detector also varied only 3% from the calculated TPS doses,
despite its decrease in sensitivity with increased dose rate. Its angular response
varied by only 3% over the range −150◦ to 90◦ at a 50 mm source–to–detector
distance. They found that the BrachyFOD was the most accurate of all four detectors
with the most desirable characteristics for in–vivo measurement in brachytherapy. It
also only varied by 3% from the predicted TPS doses up to 100 mm, beyond which
the TPS data do not match Monte Carlo data so it is not recommended to use TPS
data after this point. Its angular dependence was less than 2% [85].

The MOSFET detector was also found to be good for in–vivo measurements
as it has a small size and real–time measurement capability. Its disadvantages
included low sensitivity and angular dependence (varied by 10%). This study found
that for distances greater than 50 mm from the source, readings of the MOSFET
were affected by statistical uncertainty of 30–40% larger than the theoretical values.
At distances of more than 100 mm from the source, MOSFETs were found not to
be sensitive enough to provide any reading [85]. However for measurements of
absorbed dose to the rectum in prostate brachytherapy, the distances important for
measurement are within 50 mm so this disadvantage should not be an issue in this
case.

Diode detectors allow for real–time readout, are mechanically rugged, and
have small sensitive volumes, high sensitivity and high spatial resolution [75, 87]. A
disadvantage is their energy dependence at low energies, which was investigated by
Saini and Zhu (2007) for several commercially available diode detectors, and found
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to be dependent on the type and geometry of the buildup material of the diode [87].

A similar study to that being carried out here was done by Seymour et al. in
2011, using a PTW diode array type 9112 inside a geometric replica ultrasound
probe. This study aimed to provide a method of reproducing the position of the
detector between simulation and actual treatment to reduce uncertainty arising from
differences in detector position. Four out of the five diodes showed variations in
measurement with increased distance from the source with the average discrepancy
between measured and TPS calculated doses being −0.14% ± 3.2%. However,
trends were unclear. Radial dose dependence varied by an average of ±3% but
varied in the longitudinal direction by −3% to +11%. Angular dependence was
thought to be due in part to the slight rotation (both radial and longitudinal) of the
diodes compared to each other. The variation of response with temperature was
0.2% over the range 23–35◦ [5].

For the patient measurements in the Seymour et al.

study, the deviation be-

tween the measured dose and that predicted by the TPS were compared. Deviations
were found to range from −42% to +35% and 71.1% of measurements had less
than a 10% deviation from the TPS. The diode that was placed in a plane almost
perpendicular to the central region of the prostate showed the highest agreement
(86.8%) to within 10% of the TPS data, and also received the highest signal out of
all five diodes. 95.8% of measurements agreed within 20% of the TPS doses. Part of
the difference was attributed to positional uncertainty, which for ±0.5 mm is 10% at
10 mm from the source. This uncertainty decreases with distance due to the inverse
square law. If the probe is to be used by departments on a regular basis, this study
identified that adequate pain relief for probe insertion needs to be administered,
which they found was not always available [5].

Radiochromic film is used as a radiation detector by changing colour after exposure to ionising radiation. This occurs when the photo monomer molecules
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in the film, which are colourless, undergo a chemical change due to the energy
transfer from the incoming photons/particles.

This colour change is what is

measured to determine optical density, which is ultimately proportional to the dose
deposited [78]. EBT film was utilised in–vivo by Hardcastle et al. (2009) to measure
the rectal wall dose and hence verify the uncertainty of various TPSs. The film was
wrapped around an ERB in a spiral geometry to be inserted into a phantom rectal
cavity [88]. Film is commonly used for surface measurements, for example, for
patients receiving radiation therapy to the breast, which is associated with acute and
late skin toxicity [89–91].

Whilst ionisation chambers are not good for dosimetry at air/skin interfaces
like the rectal wall, they are used for reference measurements. An ionisation chamber consists of two electrodes (the central collecting electrode and the conductive
outer wall) separated by a gas–filled cavity. Leakage current is reduced by an
insulator between the two electrodes, as well as the presence of a guard electrode,
which directs the leakage current to ground so it is not collected by the collecting
electrode. Ionisation chambers can be directly read out and do not have much
variation in sensitivity over their lifetime [92]. In a previous study by Hardcastle et
al. (2010), dual MOSFETs were normalised to ionisation chamber measurements
using a 6 MV photon beam and the detectors were placed at the centre of an
IMRT phantom. The dual MOSFETs were found to agree within 2.5% of the dose
measured by the ionisation chambers over a range of beam angles [3].

2.8

MOSFET Detectors

MOSFET detectors are based on field effect transistors, which are made up of source,
gate and drain terminals, that are then connected to the silicon dioxide (SiO2 ) layer
(gate terminal) and silicon (Si) substrate. For an n–type MOSFET (most available
MOSFET detectors), shown in Figure 2.2, the source and drain are of n–type material, with the Si being the opposite (i.e. p–type) [93]. A physical characteristic of the
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Figure 2.2 n-MOSFET detector schematic

MOSFET detector is the epoxy ‘bubble’, usually of about 1 mm thickness, which is
used to protect the electronics from external effects. Another reason for the use of
the epoxy bubble is to provide a water equivalent depth (WED) for the detector: for
example, an epoxy thickness of 1 mm would give a WED of around 1.8 mm at an
energy of 6 MV [84, 94].
MOSFET detectors are suitable for in–vivo dosimetry due to their small size and
portability for easy placement. Their ability for instant readout allows the dose
delivered to the patient to be monitored, and as well as this, the signal is permanently
stored [6, 81].

When ionising radiation strikes the gate oxide of the MOSFET, electron–hole
pairs are created and the holes that do not undergo recombination then move
towards the interface between the SiO2 and the p–type Si substrate. A positive
build–up charge is created when some of these holes are trapped near the interface
(Figure 2.2). At a critical gate bias, known as the threshold voltage, an inversion
layer (inversion of conductivity between drain and source) is formed, allowing a
fixed current to flow in the n–type channel between the drain and source. This
threshold voltage shift is proportional to absorbed dose in the gate oxide [81, 86, 93].
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MOSFETs can undergo irradiation in either active or passive mode, which
means with or without a positive gate bias voltage respectively. Active mode is
employed to increase the sensitivity and linearity of the MOSFET’s response by
reducing recombination of the electron–hole pairs, hence more holes are trapped,
hence a larger difference in threshold voltage [81, 86].

Other desirable characteristics of the MOSFET detector that have been reported are its tissue equivalence at higher energies, negligible attenuation of
radiation, low power requirement and the fact that it can be used without attachment
to cables if needed [6, 81, 84]. It is also waterproof, which is important in in–vivo
dosimetry, and does not need to undergo procedures such as annealing, unlike
thermoluminscent dosimeters (TLDs) [95]. The MOSFET’s good spatial resolution
makes it ideal for use in high dose gradient regions [86]. This detector is also
relatively inexpensive [84].

Less desirable characteristics of the MOSFET include energy dependence,
due to an over–response at low energies caused by the Z number dependence of the
photoelectric effect and also recombination of electron–hole pairs [95,96], especially
for less than 300 keV photons with the peak value occuring at about 40 keV [96].
However, an under–response may also be observed at lower energies due to absorption by detector casing [95]. The user should be aware that a voltage shift may also
be caused by a shift in temperature of up to 4–5 mV/◦ C. This can be corrected for by
the use of a dual MOSFET, where each MOSFET operates at a different gate voltage
and the difference between these voltage shifts between MOSFETs is proportional
to absorbed dose. This difference is temperature independent [81].

MOSFETs have previously been used to measure rectal dose in in–vivo dosimetry for
HDR brachytherapy, and one study by Haughey, Coalter and Mugabe in 2011 aimed
to evaluate whether linear array MOSFET detectors were suitable for measurement
of rectal dose during HDR brachytherapy treatments. Their study included twenty
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two prostate needle implant patients, with two fractions each, and four gynaecology
patients with seven fractions altogether. A MOSFET array was inserted into the
rectum inside a flatus tube. MOSFETs contain an epoxy ‘bubble’, with MOSFET
arrays having a smaller epoxy bubble per detector than single detectors. The authors
also faced the bubble away from source where it was possible to do so [6].

Measurements were compared to a TPS calculation using a 10 Ci source.

In

particular, the angular dependence had a large effect on the detector response,
with results showing differences of up to 30%, especially in the polar plane.
The authors discuss the difficulty in taking angular dependence into account in
HDR brachytherapy due to the multiple stopping positions of the source. The
larger epoxy bubble of the single MOSFET seemed to cause a greater angular
dependence on that side. In total, 33% of measured readings for the prostate case
agreed to within ±10% of the calculated point dose from the TPS. However, if
extending the radius of the TPS dose to within 5 mm of the MOSFET position,
there was an agreement of 75%. The gynaecological case had an agreement of
42% to within ±10% between the measured results and calculated point dose
from the TPS. A variability of dose measurements of the TPS between observers
of 8.5% was seen.

The authors conclude that MOSFETs are not suitable for

in–vivo dosimetry of the rectum in HDR brachytherapy due to their angular dependence and also the fact that their exact position is not known during treatment [6].

The main reason as to why MOSFETs were found to be unsuitable for rectal
in–vivo dosimetry was the epoxy bubble, which increases the effective depth of
measurement. To allow for measurements of radiation dose to the rectal mucosa,
TM

the MOSkin

detector is a more appropriate choice. This detector was designed

to measure at a depth relevant for surface dosimetry, hence the build–up layer of
the detector has an effective depth of about 70 µm [97], which will be discussed
in the next section. The detectors in this study faced the rectal wall, so the very
thin build–up layer allowed measurements of only 70 µm out from the rectal wall;
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making the MOSkin

an ideal interface detector.

A study by Cheung, Butson and Yu (2009) utilised a type of MOSFET that
had been redesigned by the University of Wollongong and included the use of the
Clinical Semiconductor Dosimetry System (CSDS) MOSFET dosimetry system.
The MOSFET was a dual k type RADFET on an epoxy bubble surrounding (that
was more tissue equivalent than the MOSFET chip), and was known as the ‘CSDS
MOSFET’. This study aimed to investigate the effect of energy dependence of the
MOSFET for 50 kVp to 10 MVp x-rays by analysing five detectors that were at
different stages of their lifetime. It also looked at the effect of sensitivity dependence
of the MOSFET at the energies of 100 kVp, 250 kVp and 6 MVp and at different
stages of detector lifetime by measuring the change in threshold voltage [98].

The results showed that the radiation dose history of the MOSFET did not
have a significant effect on the energy dependence. They did however show a
difference in sensitivity with energy, with the peak sensitivity occurring at 75 kVp
(over response of 3.2 times), decreasing on either side of this. This over response
is less than that of other semiconductor detectors such as the T&N (Thomson and
Nielsen) MOSFET (4.3 at 31 keV) and silicon diodes (6.43 at 49 keV). MOSFETs
have been shown to exhibit decreased sensitivity as the dose increases because of
a build–up of holes at the Si–SiO2 interface due to the changes in the effective
electric field. From these results, correction factors could be determined and once
applied; an approximate linear response for sensitivity was observed for these
doses. The authors recommend that sensitivity corrections should be applied to
MOSFET readings, especially for readings at lower energies, and corrections should
be monitored over the lifetime of the detector to ensure they are still appropriate [98].

Gopiraj, Billimagga and Ramasubramanian (2008) completed a study to observe the performance characteristics of two different MOSFET detectors: the low
sensitivity TN502RD and high sensitivity TN1002RD MOSFET, using external
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beam radiation therapy. These detectors were evaluated for Co–60, 6 MV and 15
MV photon EBRT in terms of entrance/exit dose measurements in in–vivo dosimetry.
The characteristics of reproducibility, constancy (short and long term), linearity,
angular dependence, energy dependence, source–to–surface distance (SSD) dependence and field size dependence were measured. The results demonstrated very
good reproducibility of both detectors and acceptable constancy, both short and long
term. Angular dependence was found to vary by approximately 5% for the range
315◦ to 45◦ at a source–to–axis distance (SAD) of 100 cm, with MOSFETs placed
at the centre of a cylindrical phantom. For an energy of 15 MV, there was a lower
energy response than for the lower energies. There was a dependence on SSD over
the range 80 to 120 cm and a field size dependence was also shown for field sizes 3
× 3 cm2 to 30 × 30 2 [81].

As mentioned previously, another study that measured the angular response
was that by Lambert et al. (2007). The study found that the angular response of the
MOSFET detector varied by 10% for angles in the range −150◦ to 90◦ at a source–
to–detector distance of 50 mm. An 192 I source was used in the measurements. They
concluded that this may be due not only to the nonuniform epoxy bubble, but also
partly due to the positional error of ±0.5 mm in detector placement, which can
change the dose rate by 2% [85].

MOSFET detectors have also been used in LDR prostate brachytherapy to
monitor the dose in several locations following seed implantation. Cygler et al.
(2006) used dual micro–MOSFETs to measure the dose rate immediately after seed
implantation. The dose was measured inside the bladder and along the urethra. The
angular dependence of the detector was determined using a beam with an energy of
100 kVp beam, due to the effective energy being similar to that of an 125 I source [95].

The MOSFETs in the study of Cygler et al. were found to be suitable for in–
vivo dosimetry in LDR prostate brachytherapy. The angular response was measured
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and an almost isotropic response was observed for all detectors, with the largest
deviation being approximately 2.5% after normalisation to 0◦ . Variations of 10%
in calibration of the detectors demonstrated that individual calibration factors are
needed for each detector. To ensure the signal was high enough for the in–vivo
measurements; the detector was left at each position for ten minutes. In LDR, it is
not possible to reduce the dose to the urethra after the seeds have been implanted,
however, in–vivo dosimetry allows the possibility of monitoring the patient for
increased risk of complications from increased urethral dose. Under–dosing of the
base/apex of the prostate can also be monitored with the detectors and rectified by
the implantation of more seeds [95].

2.9

TM

MOSkin

Detectors

MOSFETs designed specifically for skin dosimetry, known as MOSkin

TM

detectors,

are used in both external beam radiation therapy and brachytherapy for measurement
TM

of radiation dose. MOSkin

detectors were originally developed by the Centre for

Medical Radiation Physics (CMRP) [99] to measure the dose at air/skin interfaces for
EBRT [100]. MOSkin

TM

detectors have a reproducible WED of 70 µm, which allows

for measurements at this depth [3], consistent with ICRU recommendations for skin
dosimetry [101–103]. This is the depth that corresponds to the basal layer, which is
the first radiosensitive layer of the epidermis [97, 104, 105]. To achieve this depth
measurement, a thin kapton film overlays the gate, which acts as a build–up layer.
The film also protects electronics from damage from, for example, moisture [97]. As
mentioned previously, for this study the detectors faced the rectal wall, allowing dose
TM

measurements at a point 70 µm from the rectal wall. A schematic of the MOSkin
is illustrated in Figure 2.3.
The MOSkin

TM

detector has many advantages for clinical in–vivo dosimetry. It

has a very small sensitive volume compared to other detectors, with its gate oxide
thickness measuring 0.55 µm [97].

This allows for point dose measurements
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Ribbon cable

Kapton layer

Aluminium strips

MOSFET chip
TM

Figure 2.3 MOSkin

schematic: View from above and below

in areas of high dose gradient [3], which is ideal for HDR brachytherapy and
TomoTherapy R . The whole MOSkin

TM

detector is 3 mm wide, 0.4 mm thick and,

with the cable, 330 mm long [104], making it easier to place for in–vivo dosimetry,
TM

for example, in cavities. The MOSkin

is dose rate independent and also has a

sensitivity that is not affected by changing temperature in the ranges: −60 ◦ C to
+60 ◦ C for n–MOSFETs and 20 ◦ C to 37 ◦ C for dual p–MOSFETs [86], which is
important for detector placement on/inside a patient. This detector can permanently
store accumulated dose and be read out without loss of dose information [86]. It is
available in either single or dual sensor designs [97].

Damage throughout the rectal wall is the primary cause of late radiation damage. However, measurement of the dose received by the submucosa is not possible,
as this would mean implanting a dosimeter within the wall itself. Instead, dose to the
TM

anterior rectal wall can be measured, for which the MOSkin

detector is ideal [97].

Another advantage of this detector is that the sensitivity can be altered by setting the
reader to apply either a 5 or 15 V bias voltage to the gate. This enables the detector
to measure over a larger range of doses [86, 97]. Disadvantages, or characteristics
that need to be taken into account are angular dependence, energy dependence, and
whether the detector has long term stability. MOSkin

TM

detectors have been shown

to have a decreased response with total accumulated dose [104]. Voltage creep-up
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should also be taken into account by waiting a short amount of time (∼1 minute)
post–irradiation to record the readout [97].

In 2008, Kwan et al.

completed a study examining the differences between

the PLATO TPS calculated dose and the dose measured in a solid water phantom
using the MOSkin

TM

detector and the RadFET, manufactured by REM Oxford, UK.

For a ‘full’ (i.e. water–equivalent) rectum, the results were −3.1±2% discrepancy
TM

for MOSkin

and −9.1±2% discrepancy for RadFET from the TPS. For an

‘empty’ (i.e. air–filled) rectum the discrepancies from the TPS were: −18.1±2% for
TM

MOSkin

and −21.2±2% for RadFET [4].

The results for the full rectum should have ideally been the same as the TPS.
For the large difference in results between empty rectum and TPS, it was concluded
that the TPS most likely overestimated the dose as it assumed the rectum was of
infinite size and also water–filled; when patients are effectively treated with an
empty rectum. 10–15% less dose was measured in an empty rectum compared
to when full. A smaller dose was measured by the RadFET compared with the
TM

MOSkin

, which may be due to the 1 mm difference in source–to–detector distance

due to the epoxy ‘bubble’ protecting the sensor in the RadFET. It was ruled out that
this difference was due to a defective detector by calculating the dose 1 mm further
from the source and finding that it was similar to that measured by the RadFET.
Hence it was concluded that the RadFET would be unsuitable for dosimetry of the
rectal wall in HDR brachytherapy [4].

Kwan et al.

(2009) again successfully used the MOSkin

TM

detector to deter-

mine the difference in dose to the rectal wall between the conditions that the rectum
was either empty or full. However this time, Geant4 Monte Carlo simulations were
also carried out and the results compared to the experimental data. Measurements
were completed at source–to–detector distances varying from 14–54 mm. The
results were compared to those measured by a RadFET. The RadFET’s 1 mm thick

38

Literature Review

epoxy bubble was accounted for during detector placement. By comparing the dose
measurements from an empty and full rectum, the effect of backscatter on the rectal
wall could be observed [97].

The results of this study were in agreement with values calculated by the
TG–43 formalism and the discrepancy demonstrated an increase with larger source–
to–detector distance. This was thought to be due to the detectors receiving low
dose at this depth and the low response of the detectors to this dose. Other reasons
given were the increased uncertainty with depth and incomplete scatter conditions
provided by water–equivalent phantom. The Geant4 results showed less than a
2% variation even at 50 mm source–to–detector distance. The results of this study
for absorbed dose to the anterior rectal wall in an empty rectal cavity showed a
TM

−14.7±0.2% discrepancy for MOSkin

detectors and a −13.7±0.6% discrepancy

for RadFET detectors from the dose measured in a homogeneous rectal phantom.
Results from Geant4 also showed a similar difference to the experimental results of
13.2±0.6% less dose in the empty rectum case compared to the full rectum case [97].

These results introduce the problem that detector measurements cannot be compared
straight to TPS calculations due to the large discrepancies. The TPS assumes that the
rectum is homogeneous and water–equivalent and hence the dose is overestimated,
as in reality there is not as much backscatter from an air–filled rectum [97]. The
effect of rectal heterogeneity on measured dose was found to be significant by Kwan
et al. This project will reduce the effect of rectal heterogeneity as the ultrasound
probe replica will keep the rectum at the same shape and consistency.
TM

MOSkin

detectors can be used in external beam therapy as well.

In one

particular study by Hardcastle et al. (2010), they were used in–vivo inside rectal
balloons to measure the real–time dose to the anterior rectal wall in prostate radiation
therapy [3]. The measured doses were compared to the theoretical doses of both the
3DCRT and intensity–modulated radiation therapy (IMRT) plans and found to be
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lower than these calculated doses [3].

The study by Hardcastle et al.

also demonstrates the use of the ‘dual MOS-

FET’, otherwise known as the face–to–face arrangement, which allows for
angular–independent measurements. For fraction sizes of 2–10 Gy, the detectors
demonstrated a reproducible sensitivity to within 1%, explained by the fact that
there is not much radiation damage to the detector at these doses. For the 3DCRT
plan, the measured dose was found to be 2.6% lower than the TPS dose. The
IMRT plan showed a 3.2% discrepancy between measured and planned doses [3].
These differences are much less than the brachytherapy studies by Kwan et al. most
likely due to the fact that brachytherapy has a much steeper dose gradient, making
positional errors much more of a problem.
TM

One issue with using MOSkin

detectors that was raised by Hardcastle et al.

(2010) is the error in positional reproducibility of the actual detectors during each
fraction. To get accurate results, the detector should be in the exact same position
as in the simulation CT scan so that the dose measurements are of the same area
for each fraction. This proved difficult in the Hardcastle et al. study as the rectal
balloon that contained the MOSkin

TM

detectors had the ability to move and rotate.

The authors also suggest the use of multiple detectors along the superior–inferior
axis of the balloon to increase the probability of actually getting a measurement of
the highest dose along the anterior wall of the rectum [3]. This project uses multiple
TM

MOSkin

2.10

detectors along the superior–inferior axis of the probe.

Discussion

The various treatment options for prostate cancer, such brachytherapy and EBRT,
have been discussed in this chapter, as well as the QA component of radiation therapy planning and treatment. In–vivo dosimetry using specifically the MOSFET and
TM

MOSkin

detectors was discussed, in particular the characteristics that make these
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detectors ideal for in–vivo dosimetry. From this chapter, it can be concluded that
there is still a need for improvement in dose verification in radiation therapy to the
prostate for both brachytherapy and EBRT.

Chapter 3
Comparison of HDR Brachytherapy
TPS Calculated Dose with
TM
MOSkin
Detectors Placed in
Phantom on Solid Endorectal Carrier
3.1

Probe Design and Construction
TM

The aim of this project was to determine if MOSkin

detectors could be arranged

on a replica ultrasound transducer inserted into the rectum to provide real–time
absorbed dose measurements during brachytherapy treatment to the prostate. It
TM

was hypothesised that MOSkin

detectors could be utilised to indicate dose to

the anterior rectal wall to within ±5% due to the fact that in clinical use, there is
normally a large percentage of dose points that fall outside of a 3% tolerance [106].
The effect on backscatter conditions of using a solid Perspex probe versus a hollow
TM

probe with multiple MOSkin

detectors attached was investigated. The probes

were made with the dimensions of a BK Medical 8848 Ultrasound Transducer,
which is the transducer used to guide catheter insertion in a prostate brachytherapy
procedure at SGCCC, where this project was carried out.

The experiments were designed to benchmark detector accuracy.
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implementation for HDR brachytherapy would involve a project whereby after the
catheters would be inserted into the patient, the ultrasound probe would be removed
and the replica probe inserted in its place. The patient would then have a CT scan
with the replica probe inserted. Since the treatment plan is completed on this CT
dataset, the plan also included the probe. Hence, the replica probes were made to
create the same geometric conditions during treatment, as on the plan. The detectors
were added to the probe to provide a method of monitoring the dose during treatment.
TM

The MOSkin

detectors were developed by CMRP, as previously mentioned.

They were ‘immediately’ read out after irradiation using a clinical MOSFET
semiconductor dosimetry system, which was also developed by CMRP. This device
can measure the threshold voltages of up to five detectors simultaneously. A thirty
second time interval was invoked between irradiation and read–out to allow the
slight voltage increase, or ‘voltage creep–up’ [97], to plateau. This waiting period
allowed the recombination of any charges that were not actually trapped.

Two probes were designed and made for this project, each being a replica of
the ultrasound transducer. These probes were a solid Perspex probe and a hollow
TM

Perspex probe with inserts to position four MOSkin

detectors. Each probe was 20

mm in diameter and 200 mm in length. The solid probe simulates a full rectum; the
hollow probes an empty rectum.

Originally a probe was constructed that held one detector with a channel along the
anterior side for the ribbon cable to sit in. This was the first attempt to contruct a
probe that could house a MOSkin

TM

detector before trying to accommodate mutliple

detectors, as the design would be more difficult. When designing the four–detector
probe, it was not possible to create channels for the ribbon cables. The detectors
needed to be positioned at an angle (shown in Figure 3.2) so that the cables would
not overlap the sensitive volumes. This meant that the cables had to wind around
the probe, and there was no equipment available that could make channels at this
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10.5 mm
MOSkin channel

3.1 mm

20 mm

200 mm

Figure 3.1 Probe 1: Solid Perspex probe with indentation to hold one MOSkin
including cable channel.

3.1

TM

detector,

10 mm

mm

20 mm
Detectors:

1

2

3

4
200 mm

Figure 3.2 Probe 2 and 3: Solid or hollow Perspex probe with indentations to hold four
TM
MOSkin detectors.

angle at the sub–millimeter depth that was required. It was decided that since the
probe (and hence the cables) needed to be covered by a condom, it would not matter
if the cables could not sit into the probe’s surface. Instead, they were taped down
to ensure their edges would not cause any abrasion to the patient. The condom was
also used to comply with Australian standards for infection control. It can be seen in
Figure 3.2 that the detector positions will be referred to as 1, 2, 3 and 4, with 1 being
placed most superior out of all detectors and 4 being the most inferior.

3.2

Comparison of Backscatter Differences in Solid
Water with Air Cavity and No Air Cavity

The aim of this experiment was to compare the absorbed dose to the anterior rectal
wall when there was an air cavity present in solid water and when there was no air
cavity, to determine whether there was a difference in backscatter conditions. The
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solid water used was CIRS Plastic Water R LR.
TM

3.2.1

MOSkin
TM

MOSkin

Detector Calibration

detectors were calibrated with a 10 Ci

192

Ir HDR brachytherapy source

in solid water. The threshold voltage was measured at different source–to–detector
distances from 10.0 ± 0.5 mm to 43.0 ± 0.5 mm and the time recorded to determine
voltage/time values. These were compared to dose rates (cGy/hr) that were calculated using the TG–43 formalism. The source strength was taken as 40300 U (where
U = cGy.cm2 /hr) for 192 Ir with a 0.2 mm Iron (Fe) casing [20]. The average calibration factor was determined to be 2.45 ± 0.02 mV/cGy. However, if uncertainty in
source–to–detector distance is accounted for (i.e. ±0.5 mm); then the uncertainty in
calibration factor increases. A larger uncertainty would exist for the shorter source–
to–detector distances, especially in the higher dose gradient region.

3.2.2

Percentage Depth Dose Comparison for Air Cavity and No
Air Cavity

3.2.2.1

Methodology

Percentage depth dose (PDD) measurements were taken in solid water with the three
different conditions of: no air cavity, cylindrical air cavity (21 mm diameter × 90
mm3 ) and cuboid air cavity (20 × 20 × 90 mm3 ). The two different cavities were
utilised to determine if a difference in shape caused a difference in scattering conditions and hence a difference in absorbed dose. The source–to–detector distance was
increased from 10 mm to 43 mm, which were arbitrarily chosen. Three voltage readings were aquired over a period of time (V/s) at each of these distances and converted
to dose using the calibration factors already determined. The average absorbed dose
at each distance was found. The uncertainty was determined by using Student’s t–
test, which can be used for very small sample sizes (i.e. three measurements) [107]
TM

and has been used previously in a rectal dosimetry study using MOSkin
tors [108]. All results were normalised the to ‘no cavity’ results.

detec-
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Percentage Depth Dose Curves for 10 Ci Ir-192
Source in Solid Water
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Figure 3.3 Graph of percentage depth dose (PDD) curves in solid water (NB: All measurements normalised to the ‘no cavity’ measurements).

3.2.2.2

Results

PDD measurements were compared for having no air cavity, a cuboid air cavity and
cylindrical air cavity in solid water. The results are shown in Figure 3.3.
The results were normalised to the ‘no cavity’ measurements. The PDD curves
all follow a similar trend, which is expected for these types of curves (i.e. dose
rate decreasing with increasing thickness of material between source and detector).
Measurements with no cavity were slightly higher than both cavity (cylindrical and
cuboid) measurements. This was expected due to the increased backscatter when
there was no cavity (i.e. backscatter from the solid water) compared to when there
was a cavity (i.e. air). Both cavities produced similar results.

As mentioned in the methodology, the uncertainty in percentage depth dose
was determined using Student’s t–test. Sample size (N) was equal to 3, hence
there was N−1 = 2 degrees of freedom (d.f.) and the t–value was 4.303 for a 95%
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confidence level. The uncertainty was then also normalised. There was a large
uncertainty in percentage dose at 10 mm for no cavity, as this was very close to the
source so a small uncertainty in detector placement can mean large uncertainty in
dose. Note that there is no data point for the cuboid cavity at 10 mm. This was
because the data was taken simultaneously with another experiment, and due to time
constraints with the machine, the data that was gathered from this experiment had to
be utilised.
3.2.2.3

Discussion

When no air cavity was present, absorbed dose measurements were slightly higher
than both cavity measurements of absorbed dose, due to the increased backscatter
material. Whether the cavity was cylindrical or cuboid produced negligible difference in results.

3.2.3

Comparison of Backscatter for Air Cavity and No Air Cavity with Change in Angle Between Source and Detector

The aim of this experiment was to compare the absorbed dose to the anterior rectal
wall when there was an air cavity present and when there was no air cavity, for
different angles (θ) between the horizontal plane at the source and the depression
to the detector (Figure 3.4). The absorbed dose was measured at increasing offset
distances between the 192 Ir source and the MOSkin

TM

detector, hence it was measured

as the angle (θ) decreased.
The change in θ results in different scatter conditions between the case of air cavity
and no air cavity. The purpose of this experiment was to determine if the difference
in dose rate at any of these angles was great enough to warrant creating a hollow
Perspex probe, which would then be compared to the solid Perspex probe.
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Ir source

θ

15 mm

MOSkin

TM

Figure 3.4 Experimental set–up of source relative to MOSkin

3.2.3.1

detector.

Methodology

Solid water slabs of various thicknesses were used to create a phantom with no air
cavity. For the cavity measurements, only a cylindrical cavity was used due to the
similarity in results found between the cylindrical and cuboid cavities for the PDD
measurements. The cylindrical shape was chosen due to the fact that this geometry
would be used later on for the probe construction. For the cavity, solid water with a
21 mm diameter cavity was used with the detector taped to the anterior wall of the
TM

cavity. The MOSkin

detector was placed at a distance of 15 mm and then 30 mm

from the source, for comparison. It was decided that these two set–ups would be
completed simultaneously (with one on top of the other) to help minimise set–up
errors, which were initially causing problems with this experiment.

For both cavity and no cavity, the source was stepped away (so that θ decreased) from the point just past the tip of the detector (i.e. 3 mm superior to the
detector), so that the maximum would not be missed. The source was stopped at
arbitrary increments of 3–6 mm where measurements were taken. Measurements
of absorbed dose to the anterior rectal wall for the cavity and measurements of
absorbed dose to the anterior rectal wall for no cavity were compared.
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Dose Rates Measured by MOSkin Detectors for Cylindrical Cavity
for Source-to-Detector Distance of 15 mm in Solid Water
Cavity
No Cavity

Dose Rate (cGy/s)
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-10
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Offset (mm)

Figure 3.5 Comparison of absorbed dose to anterior rectal wall with air cavity and no air
cavity for increasing offset distance at source–to–detector distance of 15 mm.

3.2.3.2

Results

Measurements of absorbed dose to the anterior rectal wall where a cavity was present
and where no cavity was present were carried out at different offset distances. This is
shown in Figures 3.5 and 3.6, where the offset on the horizontal axis is the distance
measured from the position of maximum dose. Figures 3.7 and 3.8 demonstrate the
change in dose rate and these were plotted by a MOSkin

TM

detector readout program

developed at CMRP.

The uncertainty in dose rate was calculated using a Student’s t–test with N = 3, d.f.
= 2 and t–value = 4.303 for a 95% confidence level. The calibration factor used was
2.45 ± 0.02 mV/cGy, as determined previously.

At 15 mm source–to–detector distance, the maximum dose occurred at an offset distance of 0 mm. It was expected that the maximum dose would occur here
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Dose Rates Measured by MOSkin Detectors for Cylindrical Cavity
for Source-to-Detector Distance of 30 mm in Solid Water

1.3
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Figure 3.6 Comparison of absorbed dose to anterior rectal wall with air cavity and no air
cavity for increasing offset distance at source–to–detector distance of 30 mm.

Dose Rate Measured by MOSkin Detector at
15 mm Source-to-Detector Distance
300
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Figure 3.7 Comparison of dose rates using air cavity and no air cavity for increasing offset
distance at source–to–detector distance of 15 mm.
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Dose Rate Measured by MOSkin Detector at
30 mm Source-to-Detector Distance
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Figure 3.8 Comparison of dose rates using air cavity and no air cavity for increasing offset
distance at source–to–detector distance of 30 mm.

as this is the point directly above the sensitive volume of the detector. At 30 mm
source–to–detector distance, the position of maximum dose also occurred at 0 mm
offset.

For all data points, the no cavity readings were higher than the cavity readings. This was expected due to the higher amount of backscatter introduced by the
solid material. At 15 mm source–to–detector distance, as the offset increased, the
difference between cavity and no cavity decreased. When there was no offset, the
cavity measurement was found to be 17.7% less than the no cavity measurement but
at the greatest offset of 24 mm, the difference dropped down to 14.2%. This can be
seen in Figure 3.9, along with the results for a 30 mm source–to–detector distance.
At 30 mm source–to–detector distance, the error bars were quite large in comparison to how small the change in dose rate was over the change in offset distance.
Cavity measurements demonstrated a range of 6.9–13.1% lower than the no air cavity measurements, however it was difficult to determine a trend with the change in

TM

Comparison of HDR Brachytherapy TPS Calculated Dose with MOSkin
Phantom on Solid Endorectal Carrier

24

Detectors Placed in
51

Percentage Difference in Dose Rate Between
Cavity and No Cavity for Two Source-to-Detector Distances
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Figure 3.9 Graph of percentage variation in dose rates between air cavity and no air cavity
measurements for source–to–detector distances of 15 and 30 mm.

offset distance due to the larger uncertainty than for the 15 mm case. The effect of
backscatter was most likely reduced at depth due to the attenuation and scatter of the
primary photons before they reached the detector. The source was also not a point
source, but a line source. This means that there were less photons being emitted from
the two ends of the source compared to the amount emitted from along the length.
Hence, when θ was smaller than 90◦ , less photons were being emitted at this angle
to the detector compared to when θ = 90◦ . The attenuation and scatter also explains
the less pronounced decrease in dose rate with offset distance (shallower curve) at 30
mm source–to–detector distance when compared to 15 mm.
3.2.3.3

Discussion

It can be concluded that at shorter source–to–detector distances, there was a greater
effect of the difference in backscatter observed between the conditions of cavity and
no cavity. As well as this, from the 15 mm source–to–detector distance results, it
can be observed that a greater effect of backscatter occurs with a smaller offset dis-
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tance. Due to the difference in backscatter between the conditions of cavity and no
cavity that were observed in this experiment, it was expected that there would be a
difference for the solid and hollow probes as well.

3.3

Gelatine Phantom Measurements with Single
TM
MOSkin Detectors

This experiment looked at the main aim for the brachytherapy part of the project,
TM

which was to determine that the arrangement of MOSkin

detectors on a hollow or

solid Perspex ultrasound probe replica could provide an acceptable method for taking
real–time absorbed dose measurements at the anterior rectal wall.

3.3.1

Methodology

The experimental set–up is shown in Figure 3.10. The phantom was a 15 cm ×
17 cm × 14 cm Perspex container with a 2.2 cm diameter cylindrical tube attached
horizontally inside of it. This tube allows for the insertion of the probe, as shown
in the figure, and would be running in the superior–inferior direction if the phantom
were a real patient, lying supine. The extra 2 mm of space surrounding the 2 cm
diameter probe allowed room for the detectors to be attached and a condom to cover
the probe. The phantom also contained a grid of small holes anterior to the tube so
that catheters can be inserted.
The phantom was filled with gelatine, which was prepared to the formula of a
radiotherapy bolus. The density of the gelatine was measured and found to be
0.976 ± 0.012 g/cm3 . This was 97.6% of the density of water, which demonstrates
that this composition of gelatine is an adequate material to use for tissue equivalence.

Normally, for a patient; the ultrasound probe would be inserted into the rectum to provide ultrasound–guided insertion of the catheters into the prostate. Since
the phantom was clear and the catheters could be easily observed once inside of the
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Figure 3.10 Experimental set–up of gelatine phantom and single detector probe.

phantom, this was not needed. Twenty catheters were inserted into the phantom
using a common configuration used at SGCCC. The catheters were inserted through
what would be the approximate position of the prostate in a patient (the prostate was
later drawn onto the plan).

Each of the replica probes (solid and hollow) were also inserted with four
TM

MOSkin

detectors attached. Each probe was covered using a condom, as this

would be needed for use on a patient for infection control purposes. Detectors were
used for the CT scan so that these could be observed on the scan. CT markers were
inserted into the catheters as well as being used to locate the approximate position
of the prostate on the phantom.
A Philips Brilliance 16 slice Large Bore CT Scanner was used in helical delivery
mode to scan the gelatine phantom with the replica probe inside of it. 1 mm
reconstructed slices were used and then the scan was repeated with 2 mm slices for
comparison. The pitch was 0.567 and the energy was 120 kV. The two datasets were
compared and even though 2 mm slices is the standard protocol at SGCCC; it was
decided that 1 mm slices would be used for increased accuracy in this experiment.
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Figure 3.11 Experimental set–up of gelatine phantom with probe, detectors and catheters
inserted, ready for treatment delivery.

Treatment planning was completed on an Oncentra Brachy Treatment Planning System, with 18 Gy prescribed in 2 fractions.

The plan can be seen in

Figure 3.12. A typical prostate shape was contoured on the plan, with the most
inferiorly placed detector (detector 4) trailing just inferior to the prostate volume
(Figure 3.13). Figure 3.14 shows dose points 1–4 on the plan. There was 100% dose
coverage of the prostate volume, with V200 at 9.2% (recommended to be less than
15%) and V150 at 27.3% (recommended to be less than 45%). 2 cc of the rectal
volume is recommended to receive less than 70%.
After the plan was completed, the treatment was delivered on a Nucletron HDR
unit. The MOSkin

TM

detectors replaced the dummy detectors on the probe, and

were then connected to the dosimetry system so that the threshold voltage could
be read out in real–time. The change in threshold voltage was recorded and later
converted to absorbed dose using the appropriate correction factors. The measured
absorbed doses were compared to the doses calculated by the TPS. A comparison
of absorbed dose was made for using each of the different replica probe designs.
Distance–to–Agreement (DTA) measurements were completed along with the per-
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Figure 3.12 Treatment plan on CT scan of gelatine phantom.

Figure 3.13 Prostate volume contoured on treatment plan, with catheters inserted. Relative
TM
position of MOSkin detectors can be observed.
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Figure 3.14 Treatment plan demonstrating dose distribution on slices of each of four
TM
MOSkin detectors.

centage difference comparison. DTA is defined as the distance between the location
of the point of the measured dose to its corresponding isodose line [109]. Inability
of the measured point to not only fall within the acceptable DTA distance, but to
fall outside the dose–difference measurement, indicates its failure to have produced
a good measurement in a high dose gradient region [106, 109]. For brachytherapy,
the DTA tolerance is 2 mm [110]. Petrokokkinos et al. (2011) completed an HDR
brachytherapy study using

192

I to verify their TPS dose distributions experimen-

tally and found the TPS and measured doses to be in agreement to within 5%
dose difference and 2 mm DTA. They found this agreement to be true except for in
regions close to the penumbra of the shielded applicator (up to 10% difference) [110].

The DTA value is based on the γ value, which is a method developed to quantify
the differences in dose distributions, in terms of both dose and distance. The γ
value can be separated into both the DTA and dose difference tests, and is typically
utilised to allow the easier analysis of large quantities of data from multidimensional
detectors. However, γ analysis is not simply a composite distribution, which gives
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Detector
1
2
3
4

Hollow CF
(mV/cGy)
2.29
2.47
2.47
2.48

Uncertainty Hollow
CF (mV/cGy)
0.08
0.01
0.08
0.05

Solid CF
(mV/cGy)
2.54
2.42
2.56
2.65
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Uncertainty Solid
CF (mV/cGy)
0.02
0.09
0.09
0.11

Table 3.1
TM
Calibration factors (CF) for four MOSkin
detectors on hollow and solid probes used in
HDR Brachytherapy measurements.

only a pass or fail response; but a numerical value to allow display/analysis. It does
this by scaling the difference between reference and evaluated points as a fraction
of the acceptance criteria, with a γ value of less than or equal to one being within
the accepted criteria [106, 109]. γ analysis was not utilised for this project as only
four point doses needed to be analysed, hence a numerical value to represent the
difference in a display was not required.

3.3.2

Results

The treatment plan was completed using the solid probe, since the TPS assumed
a water–filled rectum. The same plan was then delivered when having the hollow
probe inserted to be able to compare the differences in dose measured when using
the two different probes. To begin with, large deviations were observed between
measured and planned doses, so it was decided to use individual calibration factors
for each detector instead of the averaged factor found previously. Determination of
the calibration factor was completed in solid water blocks, with a source–to–detector
distance of 15 mm and delivery time of 15 s. The calibration factors are shown in
Table 3.1 for the detectors 1–4 on each of the probes.
As can be seen from this table, the calibration factors did vary, so these individual
factors were applied. The average error was less that 1.5% of the calibration factors,
with the maximum error (in detector 4, solid probe) being less than 3.5%. An example of the change in absorbed dose of each detector over time is seen in Figure 3.15.
The increase in dose was stepped, demonstrating the different source positions. The
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Dose Rate for Four MOSkin Detectors on Solid Probe
700
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Figure 3.15 Graph of change in absorbed dose measured by each of the MOSkin
over time during treatment delivery to the gelatine phantom.

TM

detectors

doses that were measured during the treatment plan delivery, along with the planned
doses, are displayed in Figures 3.16 and 3.17 and can be found in Tables A.1 and A.2
in the Appendix.
Both graphs appear to show large error, calculated using Student’s t–test. However,
the average error was only 4% of the measured doses. Observing the averaged dose
values alone, 50% of all detectors were within ±5% of the planned doses, as can be
seen in Figure 3.18. Further agreement was demonstrated by DTA measurements,
which were completed, and which demonstrated whether any measured dose
deviations were within the accepted range and are shown in Table 3.2. It can thus
be seen that all DTA values were acceptable, and hence if DTA measurements are
accounted for, 100% was observed.

For the hollow probe, the measured values for detectors 2 and 3 were within
experimental error of the TPS. Detector 1 measured a result that was outside of error
from the expected. Even though it was found to deviate from the TPS by 6.7%, its
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Using Hollow Probe
Measured
Planned

Absorbed Dose (cGy)

600

550

500

450

400

1

2

3

4

MOSkin No.

Figure 3.16 Graph of absorbed dose taken from the brachytherapy TPS data in comparison to
TM
the dose measured experimentally, using four MOSkin detectors on hollow probe in HDR
Brachytherapy.
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Figure 3.17 Graph of absorbed dose taken from the brachytherapy TPS data in comparison
TM
to the dose measured experimentally, using four MOSkin detectors on solid probe in HDR
Brachytherapy.
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Figure 3.18 Graph of percentage variation of absorbed dose between brachytherapy TPS data
TM
and measured dose, using four MOSkin detectors on solid and hollow Perspex probes.

Probe Type
Hollow
Solid

Detector
1
4
1
4

DTA (mm)
1.3
1.2
1.4
0.9

Table 3.2
Table of Distance–to–Agreement (DTA) values for HDR brachytherapy experiment utilising
TM
single MOSkin detectors.

DTA was 1.3 mm, which was within tolerance. The result from detector 4 showed
a larger deviation of 11.5% from the expected result, and was outside of the error
bounds. However, it also had an acceptable DTA of 1.2 mm.

The solid probe showed similar results, with detector 2 and 3 falling within
the error limits. Detectors 1 and 4 fell outside of experimental error, with detector
1 deviating from the expected value by 7.1%, and detector 4 by 8.1%. The results
from these two detectors had DTA values that were within tolerance. Detector 1 had
a DTA of 1.4 mm and detector 4 had a DTA of 0.9 mm.
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At this stage angular dependence was believed to be negligible as the source
positions were always within the range of 90–270◦ of the MOSkin
0◦ ). Angular dependence for MOSkin

TM

TM

detectors (at

detectors used in HDR brachytherapy

has previously been investigated [108] and results were found to demonstrate an
under–response at the back of the detector (i.e. at 180◦ ) due to the asymmetric
construction of these detectors. The Si substrate on the back of the detector caused
a larger attenuation. Even though this same study found an over–response at the
front of the detector (due to a thin Aluminium contact layer) [108], it was not
observed in this experiment for 75% of detectors. Another study found no effect of
angular dependence around the central axis of the MOSkin

TM

detector for the range

of 0–330◦ , and also no effect in the azimuthal direction [111]. However, angular
dependence was further investigated in the next experiment to determine its effect
for this particular experimental set–up. Slight positional uncertainties in the very
steep dose gradient region at the anterior rectal wall were also thought to account for
the discrepancies.

Energy dependence was also considered.

Since the range of distances from

the sources to the detectors was large (≈1.5–5 cm), the energy dependence affected
the measurements. The measurements with the source at large distances from the
detectors would contribute only a small amount to the overall dose, so calibration
was performed for the detectors at a small distance (1.5 cm). The energy dependence
effects from the source at large distances from the detectors would be minimal due
to the small relative dose contributions.

Large variations in dose between CT voxels in regions of steep dose gradients
were observed. To demonstrate this, Figure 3.19 includes uncertainty on TPS data
points. The ‘error bars’ that can be observed in this figure are not statistical, but
instead are an indication of the range of dose between adjacent voxels on the plan
dataset. This means that these bars represent the maximum and minimum dose level
that was observed over the range of dose voxels that were within the locational
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Figure 3.19 Graph demonstrating HDR brachytherapy TPS data uncertainty due to large
variations in dose between adjacent CT voxels.

uncertainty of the detector positioning. For example, for the readings taken at one
detector position, the data point corresponding to the position of the measured dose
was located just on the anterior surface of the detector on the CT image. So this
point was used to compare the experimental results with. Even though the image
was quite clear, the location of the sensitive volume of the detector was not as clear,
therefore readings were taken at five points on the detector (anterior, posterior, left
and right edges, and centre) to determine the TPS uncertainty. This was repeated on
a slice both superior and inferior to the central slice. The largest deviations (both
positive and negative) out of all these points were used to plot the TPS error bars on
the corresponding point, to demonstrate the spread of dose around this point.
The ‘error bars’ that were acquired for the TPS data were quite large and were in
the range of 2–63 cGy. This demonstrated a very large difference in dose between
adjacent voxels, adding to the uncertainty in measurements.

It was therefore

important to ensure the TPS dose reading matched the position of the measured
dose as accurately as possible. The sub millimeter resolution of the CT scan on the
planning system allowed for easy visualisation of the dual detector, which assisted
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in reducing this uncertainty. No image artifacts, such as those from the wires, were
thought to obstruct the readings from the plan.

The differences observed between solid probe results and hollow probe results
were not significant. This may be due to the fact that most source positions were
positioned at a distance greater than 15 mm source–to–detector distance so the
backscatter differences were not as pronounced than from a shorter source–to–
detector distance.

This was shown in the previous experiment that compared

backscatter for air cavity and no air cavity. Due to the similarity in results, it can be
concluded that the solid probe did not increase the dose to the anterior rectal wall,
despite the extra backscatter material introduced to the rectum when utilising this
probe.

3.3.3

Discussion

Even though only 50% of detectors on both probes demonstrated results to within
±5% of the TPS, all DTA values were within tolerance. The differences were therefore believed to be slight positional errors, although, the discrepancies may also be
due to angular dependence, but further investigation was needed. The inability to perform image–guidance to align detectors to their planned position before treatment
was a disadvantage. However, geometrically, the probes did provide an improved
method of reproducibility for the treatment of the prostate using HDR bracytherapy.

3.4

Gelatine Phantom Measurements with Dual
TM
MOSkin Detectors
TM

The measurements were repeated using dual MOSkin

detectors. The purpose of

this experiment was to improve the accuracy of the measurements at the expense of
having larger detectors. Dual MOSkin

TM

detectors are a face–to–face arrangement

of the detectors, previously reported to be successful in reducing angular dependence
by taking the average in response of the detector pair and hence cancelling the asym-
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detectors were found previously

to have an angular dependence of ±2.5% from all incident beam angles [3].
TM

3.4.1

Dual MOSkin
TM

The MOSkin

Detector Calibration

detectors were calibrated in solid water at a source–to–detector

distance of 2.5 cm to reduce the effect of discrepancies at a closer distance. Each
detector was calibrated both facing upwards and downwards, so that an average calibration factor was determined for each detector orientation. An average calibration
factor was then found between the upwards average and downwards average, as per
TM

the requirement for a dual MOSkin

detector calibration.

The average calibration factors were determined to be 2.50 ± 0.06 mV/cGy
for the upwards–facing detectors, and 2.14 ± 0.04 mV/cGy for the downwards–
facing detectors.

An average calibration factor between these two values was

therefore determined to be 2.32 ± 0.07 mV/cGy, which was applied to all dual
TM

MOSkin

detector measurements for this experiment.

3.4.2

Treatment Delivery

3.4.2.1

Methodology

This experiment was set up as per the previous measurements utilising the single
TM

MOSkin

detectors in the gelatine phantom, however, this time dual detectors were

attached to the probe. No noticeable differences between the solid and hollow probe
measurements were apparent, therefore only one probe, the solid, was utilised for
this experiment. The readout unit provided measurements of a maximum of five
single detectors, hence, only two dual detectors were possible and were placed at
positions 1 and 3 on the probe.

After the insertion of twenty catheters and the solid probe into the phantom, a
CT scan was taken of the phantom using 1 mm slices, 0.1 mm image resolution,
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Figure 3.20 Graph of absorbed dose taken from the brachytherapy TPS data in comparison
TM
to the dose measured experimentally, using four dual MOSkin detectors on solid probe in
HDR Brachytherapy.

0.567 pitch, at an energy of 120 kV. A treatment plan was created and 18 Gy
prescribed in 2 fractions with 100% of the dose covering the prostate volume. The
TM

treatment was delivered and dose read out on the dual MOSkin
3.4.2.2

detectors.

Results

The measured values were compared to the TPS data. The results obtained (Figure 3.20) demonstrated very good agreement for the two dual detectors. Table A.3 in
Appendix A also displays the results.
For dual detector 1, a discrepancy of less than 1% was observed between measured
and TPS results. For dual detector 3, a difference of less than 2% was observed.
Both measurements fell within experimental error of the TPS. DTA measurements
were not needed as the agreements were very good.

The error bars were still large, attributed to the pressure that the detectors
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were under when inside the phantom. The tight fit of the probe inside the phantom
due to the extra thickness of the dual detectors caused this variation. However,
the average error was approximately 3% of the measurements and very small
discrepancies were observed between measured and TPS data.
3.4.2.3

Discussion

These results showed that the differences observed in the single detector experiment
could be due to angular dependence, as the dual detectors showed better agreement.
TM

Hence, the probe system could be improved by utilising the dual MOSkin

detec-

tors.

3.5

Conclusion

For the single MOSkin

TM

detectors, 50% of detectors measured dose to within ±5%

of the expected TPS dose. If DTA measurements were accounted for, then all measurements were within agreement of the TPS, as all DTA values were acceptable.
The differences between results produced from utilising the hollow and solid probes
were negligible. Measurements using dual MOSkin

TM

detectors demonstrated 100%

agreement between measured and TPS doses. DTA measurements were therefore
not required, which would be ideal in a clinical situation, where time is a limitation.
Hence, the 100% agreement demonstrated by the dual detectors would be beneficial over the single detectors, which required DTA measurements to bring all results
within agreement of the TPS doses. The discrepancies observed in the single detector experiment were attributed to angular dependence; however, slight positional
deviations in the high dose gradient region can also explain discrepancies.

Chapter 4
Comparison of TomoTherapy R TPS
TM
Calculated Dose with MOSkin
Detectors Placed in Phantom on Solid
Endorectal Carrier
The next aim of the project was to test if the probe and MOSkin

TM

detectors were

acceptable for use during a prostate boost treatment using Helical TomoTherapy R .
The probe would assist in immobilisation of the target geometry for improved accuracy in plan delivery, while the MOSkin

TM

detectors mounted on the probe could

measure the dose to the rectal wall in real time. The high dose gradient region
where the rectum is positioned means positional accuracy is extremely important
(Figure 4.1).

4.1

Treatment Planning and Equipment

The TomoTherapy R boost was a hypofractionated schedule of 21.1 Gy in 2
fractions. After further studies have been completed, this boost will be followed by
IMRT with a prescription of approximately 46 Gy in 23 fractions. Although this
prescription is currently being investigated by preliminary studies, hypofractionated
treatment delivery to the prostate has been previously shown to produce favourable
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Figure 4.1 Dose map of TomoTherapy R prostate treatment plan.

results [53–55], as discussed in Section 2.3.

Approximately a 10.5 Gy fraction is usually delivered in three parts as the patient passes through the TomoTherapy R unit, with 3.5 Gy delivered per pass. Thus,
in theory, the dose can be verified and corrected for after the first pass, before the
TM

next part of the fraction is delivered. Again, the hypothesis was that MOSkin
detectors could be deployed to indicate dose to the rectum within ±5%.

This method was tested using a TomoTherapy R unit at Liverpool Hospital, New
South Wales.

The TomoTherapy R Hi–Art R treatment planning system was

utilised. An IMRT Head and Torso Freepoint Phantom (CIRS, model 002H9K) was
used for these measurements. This phantom is constructed from tissue equivalent,
epoxy materials with cylindrical cavities that allow rods to be inserted, for example,
rods that can hold an ionisation chamber or rods made of bone equivalent material.
The cylindrical cavities can also be rotated to be placed in different positions [112].
It is these cavities into which the probes can be inserted.
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The Rectafix R system has been developed to improve positioning and immobilisation in the treatment of the prostate through EBRT, for both proton and
photon boosts [7, 8]. The replica probes utilised in this experiment were modelled
similarly to the Rectafix R but were also combined with a one dimensional array
of MOSkin

TM

detectors. The Rectafix R and replica probes were both composed

of Perspex [8]. The mass densities for the Rectafix R and also the probes were
1.09–1.12 g/cm3 . The solid and hollow probes that were designed for this project
had a diameter of only 20 mm, however the phantom cavities have a diameter of 25
mm. Therefore Perspex tubing was used to create another layer around the probes
so they could fit properly inside the phantom.

IMRT Phantom

Rod
MOSkin Detector
Detector
MOSkin
Probe
Probe

Treatment Couch

Rotating Cylindar
Cylindar
Rotating
Rotating Cylindar

TM

Figure 4.2 Experimental set–up of IMRT phantom with MOSkin

detector on probe.

Megavoltage (MV) CT scans using the TomoTherapy R unit at approximately 3.5
TM

MV [113] were first taken of the phantom with the probes and a single MOSkin
TM

detector inserted. However, on some of the images the MOSkin

detectors were

not clearly visualised, so kilovoltage (kV) CT data sets were obtained instead. The
planning CT scans were taken using a Siemens Sensation 4 Multi–slice CT Scanner,
and these images were aligned with those taken prior to the treatment delivery for
image guidance.
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Treatment plans were completed on the datasets so that the TPS dose calculated at the positions of the detectors on the scan could be determined and later
compared to the measured dose. A patient’s treatment plan was used and adapted
to the phantom shape so that realistic PTVs and OARs could be overlayed onto
the phantom plan. The prescription for a prostate treatment plan using Helical
TomoTherapy R at Liverpool hospital is 19 Gy in 2 fractions prescribed to the PTV.
To achieve the sharp dose fall–off, an inhomogeneous distribution is acceptable.
Typically a prescription is 80–90% of the target maximum dose to ensure the tumour
boundary is on the steepest part of the dose gradient. This is achieved by setting the
dose prescription to 21.1 Gy, where 90% (i.e. 19 Gy) of the target maximum should
cover at least 95% of the PTV.

The aim was to limit the rectal dose to 14–16 Gy, with the maximum occurring in the overlap region between rectum and PTV. Due to this overlap, where
necessary, the PTV adjacent to the rectal volume may receive a minimum dose of 16
Gy. Otherwise a total dose of 19 Gy should be delivered to the PTV. The minimum
dose to the CTV is 19 Gy and the maximum dose to the urethra is 21 Gy. These
objectives were achieved for all plans used in this experiment. On each plan, the
co–ordinates of each detector were determined, and the dose read out at these points.
These readings were divided into six fractions and compared to the experimental
results.

4.2

TM

MOSkin

Angular Dependence

Consideration of angular dependence is important for using MOSkin

TM

detectors

in TomoTherapy R due to the helical delivery of dose. MOSFET detectors have
demonstrated an angular dependence in the past [6, 85], so this needed to be
determined for the current study. However, due to the fact that they cancel out
the asymmetric shape of the MOSFET; dual MOSFETs, were found previously to
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Figure 4.3 Plan of composite uniform distribution for calibration.

have an angular dependence of ±2.5% from all incident beam angles, and hence
they can be used for treatments delivered by rotation such as TomoTherapy R [3].
It was hypothesised that a single detector without the composite spatial resolution
increase would more precisely indicate the rectal wall interface dose where the dose
gradient may change rapidly. The use of single MOSkin
investigated initially, before investigating dual MOSkin

TM

TM

detectors was therefore

detectors.

TomoTherapy R is a rotational treatment with different beamlets approaching
from different angles of rotation and it is therefore very difficult to take angular
dependence into account. A plan with a composite uniform dose distribution was
created and delivered helically and then measurements were taken at θ = 0◦ , 90◦
and 180◦ using four MOSkin

TM

detectors to observe any potential effect of angular

dependence. It was named a ‘composite uniform dose distribution’ as it was just a
low dose gradient distribution into which the detectors were placed. The differences
in readings between all angles were ≤2% for 75% of measurements, and <5% for
92% of measurements. Hence, the detector calibration was performed by delivering
this composite uniform dose distribution so that the absorbed dose on the detector
would be from all angles. For the actual experiment, measurements were taken at
three different angles to see if there was any effect, as will be outlined in Section 4.3.
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TomoTherapy R Measurements with Single
TM
MOSkin Detectors and IMRT Phantom
TM

4.3.1

MOSkin

4.3.1.1

Methodology
TM

The MOSkin

Detector Calibration

detectors were calibrated using the TomoTherapy R unit (approxi-

mately 6 MV [113]) with a 5 × 40 cm2 field and a composite uniform dose delivered
TM

helically (shown in Figure 4.3). The solid probe was utilised with four MOSkin

detectors in the IMRT phantom. The composite uniform dose allowed the effect of
angular dependence to be minimised as the beamlet weights would not be heavily
weighted from any angle (except to account for greater lateral thickness of body
contour) as there were no avoidance structures or OARs involved. The measured
voltage readings by the detectors were compared to the TPS data to determine the
calibration factors measured in mV/cGy. The plan in Figure 4.3 demonstrates the
composite uniform dose distribution.

The dose measured by the MOSkin

TM

detectors was also verified by a CC13

ionisation chamber in the IMRT phantom. The phantom was scanned with a CC13
ionisation chamber inserted into a solid water equivalent rod. A plan was created
and dose was observed to be uniform over the whole rod and chamber. Due to this
uniform distribution, readings of absorbed dose from the TPS were taken at the
position that the MOSkin

TM

detectors would be positioned on the probe, and then

compared to the ionisation chamber reading.

To test whether the actual MOSkin

TM

detectors were capable of measuring the

dose that was planned, a single detector was placed in a region of low dose gradient,
using one of the prostate treatment plans. The reason for this was to determine
whether discrepancies between measured and planned doses were due to the actual
detector, or the high dose gradient that the detectors would later be positioned in.
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The point chosen for this was the isocentre, which was in the middle of the PTV.

This measurement was also verified by a CC13 ionisation chamber. However,
the identical reference point for measurement with both ionisation chamber and
TM

MOSkin

could not be matched, due to the dimensions and physical location
TM

within the probe. The MOSkin

was at surface of the probe, whilst the ionisation

chamber was at the centre. This meant that the dose agreement needed to be reported
separately and compared to the TPS dose at two different locations.
4.3.1.2

Results

For calibration, the absorbed doses were determined from a plan with a composite
TM

uniform dose distribution. The changes in voltage (∆V) across four MOSkin

detectors were compared to the corresponding planned dose readings. The readings
TM

and calibration factors (CF) for four MOSkin

detectors using the solid probe are

displayed in Table 4.1.

As can be observed from the table, the calibration factors were very close in
value to each other, which is what was expected in a uniform field. The largest
deviation was less than 2%. This dose was verified by the CC13 ionisation chamber,
TM

which the MOSkin

detectors were calibrated against. This calibration factor was

determined to be 2.4 ± 0.1 mV/cGy. The errors in the calibration factors were
determined by taking into account uncertainty for both the voltage readings and
dose measurement from the plan. The error in voltage reading was ±1 mV, as this
was the smallest reading that the reader could measure to. The dose per fraction
uncertainty was taken to be 0.1 cGy as this was determined to be a reasonable
estimate when reading the dose from the plan. An average of all calibration factors
from Table 4.1 was taken and found to be 2.382 ± 0.027 mV/cGy so this was taken
to be the calibration for all MOSkin

TM

detectors for this experiment. The uncertainty

was calculated using Student’s t–test, with N = 4, d.f. = 3, and t–value = 3.182 for a
95% confidence level.
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Detector
1
2
3
4

∆V (mV)
247.1
248.2
250.1
249.0

CF (mV/cGy)
2.400
2.385
2.359
2.386
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CF Uncertainty (mV/cGy)
0.004
0.004
0.004
0.004

Table 4.1
TM
Calibration factors for the four MOSkin detectors used in TomoTherapy R measurements.

The other uncertainty which needed to be accounted for, not only for calibration factors but for the rest of the experiment, was positional accuracy. The indents
on the probes assisted in positioning the detectors; however, there would still be
some discrepancy from the planned position. The treatment CT scan was aligned
with the planning CT scan before the dose was delivered to the detectors, however,
there would still be some set–up uncertainty between the two datasets, which needs
to be considered.
The other measurement completed was to determine whether the MOSkin

TM

detec-

tors performed well in a region of low dose gradient. Hence a single detector measured the dose in the centre of the PTV. The difference between planned and measured doses, for both MOSkin

TM

detector and CC13 ionisation chamber, was found

to be <1%. This demonstrated that possible discrepancies observed in the following
TM

experiments were not due to the inability of the MOSkin

detectors to record dose

accurately, but rather, the high dose gradient region.

4.3.2

Treatment Delivery

4.3.2.1

Methodology

The absorbed dose measurements were then carried out using MOSkin

TM

detectors

on both the solid and hollow probes. The experimental set–up is shown in Figure 4.4.
Treatment plans were completed and optimised for each of the probes; first utilising
a 2.00 × 2.00 × 2.00 mm3 dose grid (i.e. 2 mm slice thickness) for calculation and
then a 1.37 × 1.37 × 2.00 mm3 dose grid (i.e. 4 plans in total). The former is the
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Figure 4.4 Experimental set–up of IMRT phantom, probe, extra Perspex layer around probe
TM
and MOSkin detectors.

calculation grid used in a normal treatment plan for TomoTherapy R at Liverpool
Hospital; the latter is a fine dose grid to see if the results could be improved with its
utilisation. The size of the fine dose grid was determined by the size of the field of
view (FoV) when scanning the phantom, which was 35 cm2 . This was the smallest
FoV possible (and hence the smallest calculation grid possible) to encompass the
entire phantom.

The dose prescription was delivered as per the treatment plans.

Since the

TomoTherapy R TPS does not assume the rectum to be water–filled (unlike the
Brachytherapy TPS), it applies inhomogeneity corrections. Therefore there was no
need to utilise the same plan for both probes for comparison like in the brachytherapy
case. Instead, the plans were optimised for each type of probe, as well as for each
dose grid.

Measurements were taken at three different angles by rotating the probe to
quantify the effect at different positions on the rectal wall. However, the focus
was on the anterior rectal wall, as the overall effect of dose at the other locations
was not as significant, given the lower expected doses. Letting θ = 0◦ be the most
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Sagittal

Isodoses
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Figure 4.5 Hollow probe plan using 2.00 × 2.00 × 2.00 mm3 dose grid.
Transverse

Sagittal

Coronal

Isodoses
20.787
19.772
19.001
18.006
15.996
11.997
9.176
4.831

Figure 4.6 Solid probe plan using 2.00 × 2.00 × 2.00 mm3 dose grid.

anterior point of the rectal wall, the detector readings were acquired by rotating the
probe to θ = 0◦ , 90◦ and 180◦ . The measurements were repeated three times and the
average taken, and these experimental results were compared to the TPS data. The
uncertainty was determined by using Student’s t–test.
4.3.2.2

Results

2.00 × 2.00 × 2.00 mm3 Dose Grid

The planned dose prescription was deliv-

ered to the phantom and measured by the MOSkin

TM

detectors. Measurements were

completed for both the hollow and solid probes with four detectors mounted upon
each, and the probes were rotated to θ = 0◦ , 90◦ and 180◦ . The plans can be seen in
Figures 4.5 and 4.6.
Figure 4.7 is an example of the change in absorbed dose of each detector over time. It
can be seen that the dose rate increases at different times for each detector, depending
on the placement of each detector in comparison to the helical delivery of dose.
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Dose Rate for Four MOSkin Detectors
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Figure 4.7 Graph of change in absorbed dose measured by each of the MOSkin
over time.

detectors
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Figure 4.8 Graph of absorbed dose taken from the TPS data in comparison to the dose meaTM
sured experimentally, using four MOSkin detectors on the hollow Perspex probe at θ = 0◦
for the 2.00 × 2.00 × 2.00 mm3 dose grid.

The average changes in voltage were then converted to dose (D) per fraction (F)
using the calibration factor and are recorded in Tables A.4 to A.9 in Appendix A.
The plan data is also included for comparison. The errors in dose measurements
were calculated using Student’s t–test, with N equal to 3, 2 d.f. and t–value equal to
4.303 for a 95% confidence level. Figures 4.8 to 4.13 demonstrate the discrepancy
between the measured dose and the TPS data for the 2.00 × 2.00 × 2.00 mm3 dose
grid. Figures 4.14 to 4.16 show the percentage variation.
The acceptable DTA commonly used for photon beams is ≤3 mm [114, 115]. An
example of a DTA measurement can be observed in Figure 4.17.
For the 2.00 × 2.00 × 2.00 mm3 dose grid at θ = 0◦ , all measurements with the
hollow probe fell within the expected ±5%, and all agreed to within experimental
error. However, for the solid probe at this angle, all of the measurements were not
in agreement with the TPS data (i.e. 10–18% difference) and were well outside
error limits. This difference is most likely due to a positional discrepancy; possibly
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Figure 4.9 Graph of absorbed dose taken from the TPS data in comparison to the dose meaTM
sured experimentally, using four MOSkin detectors on the solid Perspex probe at θ = 0◦
for the 2.00 × 2.00 × 2.00 mm3 dose grid.
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Figure 4.10 Graph of absorbed dose taken from the TPS data in comparison to the dose
TM
measured experimentally, using four MOSkin detectors on the hollow Perspex probe at θ
= 90◦ for the 2.00 × 2.00 × 2.00 mm3 dose grid.
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Figure 4.11 Graph of absorbed dose taken from the TPS data in comparison to the dose
TM
measured experimentally, using four MOSkin detectors on the solid Perspex probe at θ =
90◦ for the 2.00 × 2.00 × 2.00 mm3 dose grid.
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Figure 4.12 Graph of absorbed dose taken from the TPS data in comparison to the dose
TM
measured experimentally, using four MOSkin detectors on the hollow Perspex probe at θ
= 180◦ for the 2.00 × 2.00 × 2.00 mm3 dose grid.
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Figure 4.13 Graph of absorbed dose taken from the TPS data in comparison to the dose
TM
measured experimentally, using four MOSkin detectors on the solid Perspex probe at θ =
180◦ for the 2.00 × 2.00 × 2.00 mm3 dose grid.
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Figure 4.14 Graph of percentage variation of absorbed dose between TPS data and measured
TM
dose, using four MOSkin detectors on solid and hollow Perspex probes at θ = 0◦ for the
2.00 × 2.00 × 2.00 mm3 dose grid.
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Figure 4.15 Graph of percentage variation of absorbed dose between TPS data and measured
TM
dose, using four MOSkin detectors on solid and hollow Perspex probes at θ = 90◦ for the
2.00 × 2.00 × 2.00 mm3 dose grid.
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Figure 4.16 Graph of percentage variation of absorbed dose between TPS data and measured
TM
dose, using four MOSkin detectors on solid and hollow Perspex probes at θ = 180◦ for the
2.00 × 2.00 × 2.00 mm3 dose grid.
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Figure 4.17 A DTA measurement and MOSkin

detectors in high dose gradient region.

a slight rotation of the probe since three out of four detectors show the same
percentage discrepancy (approximately 10%). This means that the detectors rotated
away from their corresponding isodose line. The DTA values for detectors 1 and 2
were within tolerance at 2.0 mm, however were out of tolerance for detectors 3 and
4 at 3.9 mm.

At θ = 90◦ using the hollow probe, detector 4 was in agreement with the TPS
within error. However the differences of the other three points range from 6.9–9.8%.
Of these other points, detector 2 and 3 had an acceptable DTA of 1.9 mm, however
detector 1 was outside the acceptable DTA limit at 5.9 mm. Detector 1 and 2 on
the solid probe at θ = 90◦ showed very a good agreement, with both detectors
falling within error of the planning data. However, results from detectors 3 and 4
showed approximately a 9% variation from the TPS data. The DTA for detector
3 was 2.7 mm (within tolerance) and for detector 4 was 3.9 mm (outside of tolerance).

Using the hollow probe at θ = 180◦ , there was not good agreement; with detectors 1–3 varying from TPS by 10.6–14.5%. Only the result from detector 4 was
acceptable, which fell inside the error bars. Detector 3 had a DTA of 3.9 mm and
detectors 1 and 2 had DTA values of 5.9 mm, which are all outside of the acceptable
range. The solid probe demonstrated a better agreement than the hollow probe at
this angle. Detectors 1–3 were within 5%, with 1 and 2 agreeing with the TPS to
within error. However, detector 4 had a 7.7% deviation from the TPS with a DTA
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outside tolerance of 3.9 mm.

Considering the anterior rectal wall alone, altogether 50% of measured doses
showed agreement to within ±5% of the TPS doses. However, if the acceptable
DTA measurements were taken into account, there was a total of 75% agreement.
The results from the other locations (posterior and side walls) are not as significant
due to the lower doses as these points.

The size of the dose grid was 2.00 × 2.00 × 2.00 mm3 and the implication
of this was that the position needed for measurement may have been in between
two different 2.00 × 2.00 × 2.00 mm3 voxels on the plan, resulting in two different
doses. There was also difficulty in visualising where the inner edge of the hollow
probe was on the CT image. This edge was used as a base to measure anteriorly to
where the detector was positioned on the probe. The solid probe was much easier to
visualise on the scan.

Any deviation that the more inferiorly placed detectors demonstrated may have been
due to the slight anterior angling of the rectal volume on the plan compared to the
phantom’s rectal wall. As mentioned before, a patient’s plan was adapted for the
phantom plans so that the contours for the critical organs could be used. The contour
of the rectum was curved whilst the rectal wall was perfectly straight, as can be
observed in Figure 4.18. The detectors were placed on the anterior side of the probe,
hence, they may be angled away from their corresponding isodose line.

1.37 × 1.37 × 2.00 mm3 Dose Grid

To try to improve the accuracy of the dose

reading from the TPS, a fine dose grid calculation was performed with the grid
reducing from 2.00 × 2.00 × 2.00 mm3 to 1.37 × 1.37 × 2.00 mm3 . Both solid
and hollow probe plans were re–optimised to allow for the best possible plan to
be created in each circumstance, which is ultimately what is desired for a patient’s
treatment plan. Measurements were performed again due to the re–scanning needed.
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Figure 4.18 Difference in angle between rectum contour and probe.

The results are shown in Tables A.10 to A.15 in the Appendix. Figures 4.19
to 4.24 demonstrate the discrepancy between the measured dose and the TPS data
using the fine dose grid calculation and Figures 4.25 to 4.27 show the percentage
variation.
At θ = 0◦ using the hollow probe, detector 1 agreed with the planning data within
error and detector 2 was within 3% of the TPS. Detector 3 and 4 demonstrated a
bit more deviation than was expected with 5.5 and 6.0% deviation respectively;
however, their DTA values were acceptable at 1.4 mm. The solid probe results
showed a great improvement in correlation between TPS and measurement when
compared to the previous dose grid measurements, with three detectors agreeing
with the TPS within experimental error. Although the uncertainty for detector 1 was
quite large, it still only demonstrated a difference of 3.1% from the expected value.
Detector 4 showed a variation of 12.3% from the TPS data and its DTA was not
acceptable at 4.1 mm.

For θ = 90◦ the detectors on the hollow probe measured results within good
agreement. All results were within 4% of the expected and detectors 1 and 2 were
within error. For the solid probe detectors 1, 2 and 3 agreed within uncertainty to the
planned result. Detector 4 showed a large variation of 14.4% and its DTA was 4.1
mm (outside tolerance). Both the solid and hollow probe showed a better agreement
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Figure 4.19 Graph of absorbed dose taken from the TPS data in comparison to the dose
TM
measured experimentally, using four MOSkin detectors on the hollow Perspex probe at θ
= 0◦ for the 1.37 × 1.37 × 2.00 mm3 dose grid.
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Figure 4.20 Graph of absorbed dose taken from the TPS data in comparison to the dose
TM
measured experimentally, using four MOSkin detectors on the solid Perspex probe at θ =
0◦ for the 1.37 × 1.37 × 2.00 mm3 dose grid.
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Figure 4.21 Graph of absorbed dose taken from the TPS data in comparison to the dose
TM
measured experimentally, using four MOSkin detectors on the hollow Perspex probe at θ
= 90◦ for the 1.37 × 1.37 × 2.00 mm3 dose grid.
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Figure 4.22 Graph of absorbed dose taken from the TPS data in comparison to the dose
TM
measured experimentally, using four MOSkin detectors on the solid Perspex probe at θ =
90◦ for the 1.37 × 1.37 × 2.00 mm3 dose grid.
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Figure 4.23 Graph of absorbed dose taken from the TPS data in comparison to the dose
TM
measured experimentally, using four MOSkin detectors on the hollow Perspex probe at θ
= 180◦ for the 1.37 × 1.37 × 2.00 mm3 dose grid.
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Figure 4.24 Graph of absorbed dose taken from the TPS data in comparison to the dose
TM
measured experimentally, using four MOSkin detectors on the solid Perspex probe at θ =
180◦ for the 1.37 × 1.37 × 2.00 mm3 dose grid.
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Figure 4.25 Graph of percentage variation of absorbed dose between TPS data and measured
TM
dose, using four MOSkin detectors on solid and hollow Perspex probes at θ = 0◦ for the
1.37 × 1.37 × 2.00 mm3 dose grid.
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Figure 4.26 Graph of percentage variation of absorbed dose between TPS data and measured
TM
dose, using four MOSkin detectors on solid and hollow Perspex probes at θ = 90◦ for the
1.37 × 1.37 × 2.00 mm3 dose grid.
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Figure 4.27 Graph of percentage variation of absorbed dose between TPS data and measured
TM
dose, using four MOSkin detectors on solid and hollow Perspex probes at θ = 180◦ for the
1.37 × 1.37 × 2.00 mm3 dose grid.

to the TPS than the previous dose grid.

For θ = 180◦ , all detectors on the hollow probe demonstrated results within
3.3% of the TPS data, with detectors 1–3 being within error bounds. Again, there
was much improvement from the 2 mm3 dose grid. The detectors on the solid probe
showed very good agreement with all results being within the error bounds.

At the anterior rectal wall, considering both solid and hollow probe results,
62.5% of detectors measured dose to within ±5% of the TPS. DTA results that were
within tolerance increased agreement to 87.5%, which was an improvement on the
normal dose grid.
Considering all measurements at all rectal wall positions, for the fine dose grid,
twenty out of twenty–four detectors (83%) measured dose to within ±5% of the
TPS calculated dose, compared to eleven out of twenty–four (46%) in the normal
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Dose Grid (mm3 )
2.00 × 2.00 × 2.00

Probe Type
Hollow

Angle (θ)
90◦

180◦

Solid

0◦

90◦

1.37 × 1.37 × 2.00

Hollow
Solid

180◦
0◦
0◦
90◦

Detector
1
2
3
1
2
3
1
2
3
4
3
4
4
3
4
4
4
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DTA (mm)
5.9
1.9
1.9
5.9
5.9
3.9
2.0
2.0
3.9
3.9
2.7
3.9
3.9
1.4
1.4
4.1
4.1

Table 4.2
Table of Distance–to–Agreement (DTA) values for TomoTherapy R experiment utilising sinTM
gle MOSkin detectors.

dose grid case. After consideration of DTA values (Table 4.2), further agreement
was observed. Two out of four DTA values were within the tolerance of 3 mm
for the fine dose grid, meaning out of all twenty–four measurements for this grid,
there were only three measurements that did not correlate to the TPS data (87.5%
agreement). This was compared to five out of thirteen DTA values for the normal
dose grid being acceptable, which meant eight out of all twenty–four measurements
for this dose grid did not correlate to the expected (66.7% agreement). Both hollow
and solid probes had a similar number in terms of how many measurements had
DTA values within the tolerance.

Discrepancies in the hollow probe for either dose grid were believed to be
due to the inhomogeneity in the dose distribution resulting from the air cavity.
Image artefacts were not thought to affect these readings as there were no large
perturbations in CT number around the probe position and no artefacts were visible
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by qualitative visualisation of the CT images.

Like the brachytherapy case, TPS ‘error bars’ were determined as well as experimental error by taking dose measurements from adjacent voxels. Again, these
were not statistical error bars but were found by taking the largest deviations from
all points and plotting these deviations as the uncertainty in TPS data. For example,
for the readings taken at θ = 0◦ , the TPS data point used to compare the experimental
results with, that corresponded to the position of the measured dose was located just
on the anterior edge of the probe (i.e. where the detector was actually located) on
the CT image. However, this could be difficult to visualise on the scan due to the
contrast and resolution of the display, therefore a point anterior to this point was
also taken. To account for points that may seem to be in–between two voxels in the
left/right direction, points were taken left and right of the point. The superior/inferior
direction was also accounted for by taking a point on the slice superior and inferior,
in the same anterior/posterior and left/right positions as the main data point on
the original slice. Then anterior/posterior and left/right points were taken on these
slices, as on the original slice. The largest positive and negative deviations were
used demonstrated the large spread of dose around the data point. Figure 4.28
demonstrates this.
The TPS error bars were quite large; varying up to 30 cGy from the planned data
points corresponding to the measured data points for this dose grid. By observing
these steep dose gradients, it can be seen why such a small change in position can
lead to a large change in dose, which may provide an explanation for variation
between experimental results and the TPS.

All results depended on the plan used due to the differences in position that
the detectors can be placed in the high dose gradient regions. Figure 4.1 demonstrated the approximate position of the rectum in this high dose gradient region.
The results demonstrated that even with a fine dose grid, the reliance on positional
accuracy in a high dose gradient region still has a significant effect on the results.
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Figure 4.28 Graph demonstrating TomoTherapy R TPS data uncertainty due to large
varaitions in dose between adjacent CT voxels.

The difference in dose across a 1.37 × 1.37 × 2.00 mm3 voxel can still be quite
large when compared to the size of the sensitive volume of a MOSkin

TM

detector,

with its gate oxide thickness measuring 0.55 µm [97] and the thickness of the entire
detector measuring only 0.4 mm [104].

Even though the plans were re–optimised for each probe type, the two plans
could still be compared in terms of which plan could deliver a lower dose to
the rectum when optimised for its own conditions. For the normal dose grid all
measurements of absorbed dose for the solid probe were lower than the hollow
probe by a range of 2.7–15.0%. For the fine dose grid the opposite can be observed,
with all bar one detector on the solid probe showing a higher dose than those on the
hollow probe by a range of 1.3–13.2%. As can be seen here; different plans would
result in a different dose distribution. Hence the results demonstrate that the solid
probe spared the rectum better in the normal dose grid case and the hollow probe
when employing the fine dose grid calculation.
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Discussion

It can be concluded that the fine dose grid calculation did indeed improve the
measurements. The fine dose grid provided a more accurate method for measuring
absorbed dose from the TPS than the normal dose grid. Then, looking at the results
for the fine dose grid, it was not clear which probe was better as there were a number
of factors to consider. The hollow probe was better as it reduced the dose to the
rectum. However, as this changed between dose grids, it may indicate that it was
not caused by a physical characteristic of the probe, and hence may change between
plans.

Another aspect to consider was that the plan using the solid probe allowed the
edge of the probe to be more easily visualised on the CT scan, using the resolution
available. This aspect therefore also improved accuracy. Both solid and hollow
probes performed equally well when using the fine dose grid in terms of deviation
from the TPS data. Therefore, if the ease with which the solid probe could be seen
on the CT scan is the dominant factor (because spatial positioning of the detector
TM

can be more clearly determined on CT), then this probe combined with MOSkin

detectors and the use of a fine dose grid calculation would be more accurate for
rectal wall dose measurements in prostate treatment using TomoTherapy R .

Discrepancies were partly attributed to positional uncertainty in the very high
dose gradient region at the anterior rectal wall. This could be investigated with
fiducial markers to improve image–guidance. Angular dependence should also be
investigated by the use of dual MOSkin

TM

detectors.

The fact that the treatment used in this experiment was a TomoTherapy R
boost, to be used in conjunction with IMRT, means that the patient may only
be required to have the probe inserted for the boost treatment. It is particularly
important to verify the dose in the boost due the large fraction sizes (approximately
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Figure 4.29 CT scan of solid probe with gold seeds imbedded in surface.

10.5 Gy per fraction), when compared to the smaller fraction sizes of the IMRT
(approximately 1.8–2 Gy per fraction). The discomfit of the probe would therefore
only need to be tolerated for two fractions instead of potentially twenty–three or
more, making the treatment easier on the patient.

4.3.3

Measurements with Inclusion of Gold Seed Fiducial
Markers

4.3.3.1

Methodology

The method utilised so far for checking probe rotation was to draw markings on the
probe that would then be aligned to the room lasers. After treatment the alignment
was checked again to ensure the probe had not rotated. To attempt to further improve
the detector positional reproducibility, fiducial markers were attached to the probe.
Since the solid probe was verified to be the best choice for rectal dose measurements
in a TomoTherapy R boost, the gold seeds were added to this probe to determine
whether this further improved positional accuracy. Holes were therefore drilled into
the solid probe, both 1.5 cm superior and 1.5 cm inferior to the detectors. In these
holes, 3 mm long gold seeds were placed, running in the superior/inferior direction,
flat to the probe’s surface.
At this time a new CT scanner was available and hence a 1 mm slice thickness for
the planning CT scan could be utilised. A plan was created, and as previously, the
dose read out at the positions of the four detectors. The dose calculation grid used
was 1.37 × 1.37 × 1.00 mm3 . Another advantage of the fiducial markers was that the
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TM

Figure 4.30 Registerd KVCT (green) and MVCT (purple) images with MOSkin
and gold seeds positioned at θ = 90◦ .

detectors

MVCT scans could be used for the pre-treatment scans. These were registered to the
KVCT image before treatment (Figures 4.30 and 4.31) and the gold seeds aligned
between the two images.
4.3.3.2

Results

The results can be seen in Tables A.16 to A.17 in the Appendix. Figures 4.32 to
4.34 demonstrate the discrepancy between the measured and planned doses. DTA
measurements were completed and are displayed in Table 4.3.
For θ = 0◦ , detector 1 was within ±5% of the planned doses, at 4.6%. For the
remaining measurements at this angle, the doses were 8.1–13.9% higher than those
of the TPS. However, their DTA measurements were all within the 3 mm tolerance
at 2.2 mm, 1.4 mm and 1.4 mm for detectors 2, 3 and 4 respectively.

For θ = 90◦ , detector 3 varied from the planned data by 2.8%. All other detectors measured doses that were 6.6–10.9% lower than the TPS doses. Detector 2
had a DTA measurement of 2.8 mm, whereas detector 1 and 4 had DTA values of
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TM

Figure 4.31 Registerd KVCT (green) and MVCT (purple) images with MOSkin
and gold seeds positioned at θ = 180◦ .
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Figure 4.32 Graph of absorbed dose taken from the TPS data in comparison to the dose
TM
measured experimentally, using four MOSkin detectors on the solid Perspex probe at θ =
0◦ for the 1.37 × 1.37 × 1.00 mm3 dose grid. Fiducial markers were attached to the probe.
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Figure 4.33 Graph of absorbed dose taken from the TPS data in comparison to the dose
TM
measured experimentally, using four MOSkin detectors on the solid Perspex probe at θ =
90◦ for the 1.37 × 1.37 × 1.00 mm3 dose grid. Fiducial markers were attached to the probe.
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Figure 4.34 Graph of absorbed dose taken from the TPS data in comparison to the dose
TM
measured experimentally, using four MOSkin detectors on the solid Perspex probe at θ =
180◦ for the 1.37 × 1.37 × 1.00 mm3 dose grid. Fiducial markers were attached to the probe.
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Angle (θ)
0◦

90◦

180◦

Detector
2
3
4
1
2
4
1
4
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DTA (mm)
2.2
1.4
1.4
4.1
2.8
3.6
4.1
4.1

Table 4.3
Table of Distance–to–Agreement (DTA) values for TomoTherapy R experiment utilising
fiducial markers on probe.

4.1 mm and 3.6 mm respectively.

At θ = 180◦ , detector 2 measured a dose that differed from the TPS by 4.8%
and detector 3 differed by 1.7%. Detectors 1 and 4 differed by 8.8% and 12.8%
from the planned doses, respectively, with a DTA measurement of 4.1 mm for both
detecttor positions.

For the anterior rectal wall, there was a 25% agreement between measured
and planned doses, however all DTA measurements were within tolerance, increasing the agreement to 100% at this location. For total measurements at all rectal wall
locations, the results showed that 33.3% of measurements fell within ±5% of the
planned doses. However, four out of eight DTA values were within tolerance. This
indicates that eight out of twelve (66.7%) measurements in total, for this part of the
experiment, corresponded to the planned doses.

It was demonstrated that the fiducial markers did not improve the results.

If

only considering the anterior rectal wall because of the higher doses at this point,
and accounting for DTA measurements that were within tolerance as well; then it
could be said that the fiducial markers did improve the agreement between measured
and TPS doses (100% agreement). However, from a clinical point of view, having
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an immediate agreement during treatment is more beneficial than needing to further
analyse results with DTA measurements.

The plan used was a new plan than previously used, and a steeper dose gradient was observed in the area that the detectors were positioned in.

These

measurements show that this steep dose gradient is problematic when taking point
dose measurements. Potentially a plan with a shallower dose gradient may have
provided a closer agreement between the detector readings and TPS doses. The
larger number of discrepancies observed in this experiment was believed to be due
to the fact that image–guidance was completed by aligning the fiducial markers
between the treatment CT scan and planning CT scan, rather than by the actual
detectors, which had been the previous method used. For correct verification of the
position of the detectors themselves, fiducial markers would need to be attached to
the actual detectors rather than the probe. However, this would not be possible as
the markers would affect the dose measured by the detectors. A more sophisticated
probe design could instead assist in improving positional accuracy of the detectors.
4.3.3.3

Discussion

From these results, it can be seen that as the gold seeds did not improve the positional
reproducibility of the detectors, the original method of marking the probe in line
with the sensitive volumes of the detectors was acceptable. Image–guidance should
attempt to match to the detectors to account for slight positional shifts. Hence, for
the remaining experiments, fiducial markers will not be utilised.

4.4

TomoTherapy R
Measurements with
TM
MOSkin Detectors and IMRT Phantom
TM

The fiducial measurements with single MOSkin

Dual

detectors demonstrated that the re-

sults thus far have not been satisfactory, therefore further investigation was completed
in the TomoTherapy R measurements. To improve the accuracy of measurements at
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the expense of having larger detectors, as in the brachytherapy case; the measurements were repeated using dual MOSkin

TM

detectors, the properties of which were

previously discussed.
TM

4.4.1

Dual MOSkin

4.4.1.1

Methodology

The MOSkin

TM

Detector Calibration

detectors were calibrated using the TomoTherapy R unit at approx-

imately 6 MV [113] using a static, 5 × 40 cm2 field at 85 cm Source–to–Surface
Distance (SSD). The detectors were placed at a depth of 1.5 cm of solid water and
voltage readings acquired. The readings were compared to CC13 ionisation chamber
dose measurements that were also taken at 1.5 cm depth of solid water to determine
the calibration factor. Each detector was calibrated facing both upwards and then
downwards, so that an average calibration factor was determined for each detector
orientation. An average calibration factor was then found between the upwards averaged calibration factor and downwards average calibration factor.
4.4.1.2

Results

The average calibration factors were determined to be 2.57 ± 0.06 mV/cGy for the
upwards–facing detectors, and 2.36 ± 0.04 mV/cGy for the downwards–facing detectors. An average calibration factor between the upwards and downwards values
was therefore determined to be 2.47 ± 0.07 mV/cGy, which was applied to all dual
TM

MOSkin

detector measurements for this experiment.

4.4.2

Treatment Delivery

4.4.2.1

Methodology

The IMRT phantom was again utilised for treatment delivery. The solid probe, having
already been determined to be the preferred probe of the two; was utilised for this
experiment. Dual MOSkin

TM

detectors were attached to the solid probe. The read–
TM

out unit was modified to support five dual MOSkin

detectors. The dose grid used
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Figure 4.35 Graph of absorbed dose taken from the TPS data in comparison to the dose
TM
measured experimentally, using four dual MOSkin detectors on solid probe at θ = 0◦ for
the 1.37 × 1.37 × 1.00 mm3 dose grid.

was the fine dose grid with a scan slice thickness of 1 mm. The probe was rotated to
θ = 0◦ , 90◦ and 180◦ , dose measurements taken at these points and compared to the
planned doses.
4.4.2.2

Results

The measured doses were compared to the planned doses and are displayed from
Figure 4.35 to Figure 4.37 and in Appendix A in Table A.19 to Table A.21. The
average error was less than 3% of the measured doses. Dual detector 1 was believed
to be slightly unstable, which was demonstrated by its larger error. The detector may
have been affected by abrasion.
At θ = 0◦ , dual detector 1 deviated by 4.2% from the TPS data, which was within
tolerance. Dual detectors 2 and 3 also agreed with the TPS, deviating from the
planned data by only 0.3% and 2.8% respectively. The result from dual detector 4
differed from the TPS by 5.3%; however, its DTA measurement was 1.3 mm, which
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Figure 4.36 Graph of absorbed dose taken from the TPS data in comparison to the dose
TM
measured experimentally, using four dual MOSkin detectors on solid probe at θ = 90◦ for
the 1.37 × 1.37 × 1.00 mm3 dose grid.
Comparison of Measured Absorbed Dose to TPS Data
ο
Using Solid Probe at θ = 180
190
Measured
Planned

Absorbed Dose (cGy)

180
170
160
150
140
130
120

1

2

3

4

Dual MOSkin No.

Figure 4.37 Graph of absorbed dose taken from the TPS data in comparison to the dose
TM
measured experimentally, using four dual MOSkin detectors on solid probe at θ = 180◦ for
the 1.37 × 1.37 × 1.00 mm3 dose grid.
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Angle (θ)
0◦
90◦
180◦

Detector
4
1
2
1
4
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DTA (mm)
1.3
4.3
2.8
3.9
2.7

Table 4.4
Table of Distance–to–Agreement (DTA) values for TomoTherapy R experiment utilising
TM
dual MOSkin detectors.

was within tolerance.

For θ = 90◦ , dual detectors 2 and 3 measured results of 0.4% and 3.5% difference from the TPS respectively. However, dual detector 1 varied by 11.9% from the
planned doses and dual detector 4 differed by 7.0%. The DTA value for dual detector
1 was 4.3 mm, which was outside of tolerance. However, the DTA measurement for
dual detector 4 was within tolerance at 2.8 mm.

For θ = 180◦ , again, dual detector 2 and 3 showed good agreement of 1.3%
and 0.9% respectively. Dual detectors 1 and 4 measured doses of 8.7% and 8.2%
variation from the TPS doses. The DTA measurement for dual detector 1 was
outside the acceptable limit at 3.9 mm, however, the DTA measurement for dual
detector 4 was within tolerance at 2.7 mm.

For the anterior rectal wall, 75% of measurements agreed to within ±5% of
the planned dose. However, detector 4 had a very small DTA measurement, and if
experimental error is taken into account; its 5.3% deviation can be considered within
the ±5% acceptance. Thus 100% agreement was observed at this location.

Considering the anterior rectal wall only, which is of greatest importance, the
dual detectors proved to be superior in comparison to the single detectors. Analysing
the results from the fine dose grid and solid probes for both single and dual
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detectors, the agreement between experimental and planned doses is 75% and 100%
respectively.

The average difference between upwards–facing and downwards–facing detectors was less than 1%. This negligible difference supports the method used in the
earlier single detector measurements to calibrate the detectors utilising the composite
uniform dose distribution. This type of dose distribution allowed an average dose
from all angles to be measured by the detectors.
4.4.2.3

Discussion

These results show that the differences observed in the single detector experiTM

ment were most likely due to angular dependence. Hence, the dual MOSkin

system would be a good method for measurements of absorbed dose in real
time for TomoTherapy R prostate boost treatments, due to the helical nature of
TomoTherapy R .

4.5

Conclusion

For the single detector experiment, 75% of measurements for the normal dose grid
were within ±5% of the TPS calculated dose at the anterior rectal wall, compared
to 87.5% for the fine dose grid, when accounting for DTA measurements. The solid
and hollow probes performed equally well when utilising the fine dose grid for
measurements at every detector location on the rectal wall. The solid probe was
determined to be the better of the two probes for the TomoTherapy R measurements,
due to the greater uncertainty in the hollow probe measurements.

25% of results were within ±5% of the TPS at the anterior rectal wall when
utilising fiducial markers on the solid probe. However, all DTA values were within
tolerance, indicating that image–guidance aligning to the detectors was more
TM

beneficial that aligning to separate fiducial markers. Dual MOSkin

detectors
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improved the single detector results, with all dual detector measurements falling
within ±5% of the planned dose at the anterior rectal wall. Angular dependence
therefore can explain the discrepancies in the single detector experiment.

Chapter 5
Conclusion and Future Research
Problems with prostate HDR brachytherapy and helical TomoTherapy R , such as
prostate movement and the very steep dose gradient covering the anterior rectal wall,
have led to uncertainty in dose to the rectal wall of the patient. Two replica probes
were introduced to improve the dosimetry of prostate radiation therapy real–time,
specifically for HDR brachytherapy and TomoTherapy R . MOSkin

TM

detectors

were chosen for this method due to their superior measurement capabilities of
absorbed dose to the anterior rectal wall, such as ability for measurements in high
dose gradient areas. This method was found to be successful, although there was
still difficulty with positional reproducibility.

Preliminary measurements in phantom were completed for both treatment modalities. For HDR brachytherapy, calibration was completed with calibration factors
determined to be in the range of 2.42 ± 0.09 mV/cGy to 2.65 ± 0.11 mV/cGy for the
single detectors, and 2.32 ± 0.07 mV/cGy for the dual detectors. Percentage depth
dose measurements demonstrated that the solid water with no cavity present resulted
in slightly higher doses than both cavity (cylindrical and cuboid) measurements, and
both cavities produced similar results. For TomoTherapy R , the differences in dose
readings between all angles were ≤2% for 75% of measurements, and <5% for 92%
of measurements when measuring dose in the composite uniform dose distribution.
The calibration factor for the single detector experiment, also determined by per107
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forming measurements in the composite uniform dose distribution, was found to be
TM

2.4 ± 0.1 mV/cGy. Measurements completed to determine whether the MOSkin

detectors performed well in a low dose gradient region, resulted in <1% difference
between measured doses and the TPS doses. The average calibration factor for the
dual detectors was determined to be 2.47 ± 0.07 mV/cGy.

For HDR brachytherapy, utilising single MOSkin

TM

detectors, the hollow and

solid probes demonstrated similar results, with 50% of detectors measuring dose
to within ±5% of the expected dose from the plan. All DTA measurements were
acceptable, meaning slight positional deviations were the most likely cause of the
differences in dose, however, angular dependence also seemed an issue. Due to
the similarity in results between the probes, it could not be determined which was
the superior choice for HDR brachytherapy to the prostate, as the solid probe did
not increase dose to the anterior rectal wall. This was despite results from the
experiment comparing cavity and no cavity in solid water blocks, demonstrating
lower doses measured for having a cavity present of 14.2–17.7% and 6.9–13.1% for
15 mm and 30 mm source–to–detector distance respectively.

Measurements with dual MOSkin

TM

detectors were then completed to investi-

gate whether discrepancies were due to angular dependence. The solid probe was
utilised, as there was no discernible difference found between the two probes and the
solid probe was the more rigid of the two. 100% agreement was determined between
measured and TPS doses to within 2%. Angular dependence could therefore explain
the differences observed in the single detector experiment.

For TomoTherapy R , utilising single detectors, two different dose grids were
compared: the normal and fine dose grids. For the fine dose grid, 62.5% of detector
measurements recorded a dose to within ±5% of the TPS calculated dose at the
anterior rectal wall, compared to 50% for the normal dose grid. Taking into account
DTA values for these results increased the agreement to 75% and 87.5% for the
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normal and fine dose grids respectively. Over all the measurements at every detector
location on the rectal wall, the solid and hollow probes performed equally well
when utilising the fine dose grid. Due to the number of measured doses agreeing
with TPS doses from each probe being equal; the probe determined to be best for
TomoTherapy R boost treatments to the prostate was the solid probe, based on
the premise that there was more uncertainty when taking measurements using the
hollow probe due to it being more difficult to observe the probe’s edge on the CT
scan.

The main source of uncertainty in this experiment was detector localisation.
It was difficult to place the detectors in the correct position, especially in a high
TM

dose gradient region. Other sources of error included the MOSkin

detectors

themselves, which could sometimes be unstable in their read–out. The detectors
could have also been affected by temperature or other physical factors, such as
abrasion. The MOSkin

TM

detector reader also has an uncertainty in the read–out.

Fiducial markers did not improve the results, with only 25% of detectors
measuring dose to within ±5% of the planned dose at the anterior rectal wall,
although all DTA values were within tolerance. This indicated that it was beneficial
to perform image–guidance aligning to the detectors, rather than to separate fiducial
markers. However, other improvements to this experiment could be made by a more
sophisticated probe design. The probes used here were effective, however, they
were not optimised for precise positioning of the detectors. For example, the detectors could only be taped down. A more permanent solution could be implemented.

The TomoTherapy R

TM

measurements were repeated utilising dual MOSkin

detectors. All detectors measured dose to within ±5% of the TPS at the anterior
rectal wall, demonstrating that angular dependence in a helical dose delivery was the
reason for previous discrepancies.
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Despite very steep dose gradients, the real time measurements of the anterior
rectal wall doses were within acceptable limits of the TPS predicted doses. Discrepancies between measured and TPS data were due to difficulties in precisely locating
each detector in the TPS dose grid, with large variations in dose between CT voxels
present in regions of steep dose gradients. The dual MOSkin

TM

system would be a

useful tool for detecting errors, such as patient shifts or incorrect set–up, in real time
during HDR brachytherapy and TomoTherapy R of the prostate.

The next step in this study is to validate the measurements with Gaf–chromic
film due to some of the larger discrepancies observed. If results are validated
appropriately, then clinical trials can begin; utilising the most ideal probe and
detector combination for the treatment modalities.

For brachytherapy, current

procedures at SGCCC would still be carried out, so the addition of the replica probe
would not significantly alter the treatment geometry. The only difference would be
replacing the ultrasound probe with the replica probe after insertion of the catheters.
The added detectors would provide dosimetric benefit. For TomoTherapy R the
patient is not normally treated with a probe inserted for standard fractionation.
However, the improvement in positional reproducibility and added detectors will
provide increased confidence in treatment delivery.
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Appendix A
Tabulated TPS and Measured Data
Detector
1
2
3
4

Planned
D/F (cGy)
531.83
577.01
580.55
490.07

Measured
D/F (cGy)
496.09
557.96
572.86
546.42

Measured
D/F
Uncertainty (cGy)
12.16
22.47
22.97
23.16

% Difference
-6.7208
-3.3016
-1.3239
11.499

Table A.1
Comparison between HDR Brachytherapy TPS data and measured dose using four single
TM
MOSkin detectors with the hollow probe.

Detector
1
2
3
4

Planned
D/F (cGy)
531.83
577.01
580.55
490.07

Measured
D/F (cGy)
494.31
564.07
580.64
529.84

Measured
D/F
Uncertainty (cGy)
23.84
23.97
34.42
26.47

% Difference
-7.0550
-2.2426
0.015491
8.1144

Table A.2
Comparison between HDR Brachytherapy TPS data and measured dose using four single
TM
MOSkin detectors with the solid probe.
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Tabulated TPS and Measured Data

Detector
1
3

Planned
D/F (cGy)
552.83
603.64

Measured
D/F (cGy)
552.68
614.49

Measured
D/F
Uncertainty (cGy)
14.66
23.15

% Difference
-0.027722
1.7979

Table A.3
Comparison between HDR Brachytherapy TPS data and measured dose using four dual
TM
MOSkin detectors with the solid probe.

Detector
1
2
3
4

Planned
D/F (cGy)
298.7
270.8
241.5
199.5

Measured
D/F (cGy)
285.5
278.0
247.3
197.9

Measured
D/F
Uncertainty (cGy)
12.8
10.8
8.1
7.3

% Difference
4.417
-2.616
-2.390
0.8156

Table A.4
TM
Comparison between TomoTherapy R TPS data and measured dose using four MOSkin
detectors with the hollow probe at θ = 0◦ for the 2.00 × 2.00 × 2.00 mm3 dose grid.

Detector
1
2
3
4

Planned
D/F (cGy)
251.8
242.3
204.0
161.3

Measured
D/F (cGy)
278.0
266.4
240.7
177.7

Measured
D/F
Uncertainty (cGy)
8.4
8.4
8.7
10.9

% Difference
-10.30
-9.949
-17.99
-10.16

Table A.5
TM
Comparison between TomoTherapy R TPS data and measured dose using four MOSkin
detectors with the solid probe at θ = 0◦ for the 2.00 × 2.00 × 2.00 mm3 dose grid.
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Tabulated TPS and Measured Data

Detector
1
2
3
4

Planned
D/F (cGy)
227.2
201.2
183.2
133.0

Measured
D/F (cGy)
204.9
187.2
173.0
129.7

Measured
D/F
Uncertainty (cGy)
1.3
1.3
1.3
1.3

% Difference
9.815
6.924
5.570
2.464

Table A.6
TM
Comparison between TomoTherapy R TPS data and measured dose using four MOSkin
detectors with the hollow probe at θ = 90◦ for the 2.00 × 2.00 × 2.00 mm3 dose grid.

Detector
1
2
3
4

Planned
D/F (cGy)
194.8
181.3
149.5
103.7

Measured
D/F (cGy)
194.0
178.1
162.7
112.8

Measured
D/F
Uncertainty (cGy)
2.1
0.6
5.7
4.3

% Difference
0.3673
1.678
-8.953
-8.892

Table A.7
TM
Comparison between TomoTherapy R TPS data and measured dose using four MOSkin
detectors with the solid probe at θ = 90◦ for the 2.00 × 2.00 × 2.00 mm3 dose grid.

Detector
1
2
3
4

Planned
D/F (cGy)
174.8
154.3
146.3
124.8

Measured
D/F (cGy)
154.9
132.0
130.8
118.5

Measured
D/F
Uncertainty (cGy)
6.5
1.6
3.2
5.9

% Difference
11.39
14.50
10.59
5.051

Table A.8
TM
Comparison between TomoTherapy R TPS data and measured dose using four MOSkin
detectors with the hollow probe at θ = 180◦ for the 2.00 × 2.00 × 2.00 mm3 dose grid.
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Tabulated TPS and Measured Data

Detector
1
2
3
4

Planned
D/F (cGy)
145.0
131.0
122.5
99.7

Measured
D/F (cGy)
148.9
128.0
127.3
107.3

Measured
D/F
Uncertainty (cGy)
5.9
5.5
2.6
3.0

% Difference
-2.686
2.257
-3.954
-7.692

Table A.9
TM
Comparison between TomoTherapy R TPS data and measured dose using four MOSkin
detectors with the solid probe at θ = 180◦ for the 2.00 × 2.00 × 2.00 mm3 dose grid.

Detector
1
2
3
4

Planned
D/F (cGy)
228.5
219.0
211.0
173.2

Measured
D/F (cGy)
231.0
213.4
222.5
183.6

Measured
D/F
Uncertainty (cGy)
4.7
2.2
5.8
7.4

% Difference
1.111
-2.554
5.451
6.025

Table A.10
TM
Comparison between TomoTherapy R TPS data and measured dose using four MOSkin
detectors with the hollow probe at θ = 0◦ for the 1.37 × 1.37 × 2.00 mm3 dose grid.

Detector
1
2
3
4

Planned
D/F (cGy)
245.2
236.5
229.2
188.3

Measured
D/F (cGy)
237.5
238.9
231.2
211.6

Measured
D/F
Uncertainty (cGy)
12.1
3.6
3.9
3.8

% Difference
-3.137
1.004
0.8778
12.35

Table A.11
TM
Comparison between TomoTherapy R TPS data and measured dose using four MOSkin
detectors with the solid probe at θ = 0◦ for the 1.37 × 1.37 × 2.00 mm3 dose grid.
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Tabulated TPS and Measured Data

Detector
1
2
3
4

Planned
D/F (cGy)
181.7
161.8
162.7
122.2

Measured
D/F (cGy)
181.1
157.4
156.6
126.9

Measured
D/F
Uncertainty (cGy)
4.3
8.1
2.8
3.4

% Difference
-0.3228
-2.720
-3.735
3.894

Table A.12
TM
Comparison between TomoTherapy R TPS data and measured dose using four MOSkin
detectors with the hollow probe at θ = 90◦ for the 1.37 × 1.37 × 2.00 mm3 dose grid.

Detector
1
2
3
4

Planned
D/F (cGy)
201.8
184.0
175.0
134.0

Measured
D/F (cGy)
200.5
189.2
172.4
153.2

Measured
D/F
Uncertainty (cGy)
6.1
5.1
3.2
13.6

% Difference
-0.6449
2.824
-1.483
14.35

Table A.13
TM
Comparison between TomoTherapy R TPS data and measured dose using four MOSkin
detectors with the solid probe at θ = 90◦ for the 1.37 × 1.37 × 2.00 mm3 dose grid.

Detector
1
2
3
4

Planned
D/F (cGy)
154.8
124.3
124.2
113.8

Measured
D/F (cGy)
158.0
121.3
125.5
110.1

Measured
D/F
Uncertainty (cGy)
4.3
6.3
4.2
2.6

% Difference
2.039
-2.418
1.094
-3.252

Table A.14
TM
Comparison between TomoTherapy R TPS data and measured dose using four MOSkin
detectors with the hollow probe at θ = 180◦ for the 1.37 × 1.37 × 2.00 mm3 dose grid.
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Tabulated TPS and Measured Data

Detector
1
2
3
4

Planned
D/F (cGy)
156.8
131.8
121.0
118.5

Measured
D/F (cGy)
157.3
129.7
119.9
117.7

Measured
D/F
Uncertainty (cGy)
3.7
3.6
4.2
2.6

% Difference
0.2917
-1.601
-0.8866
-0.6850

Table A.15
TM
Comparison between TomoTherapy R TPS data and measured dose using four MOSkin
detectors with the solid probe at θ = 180◦ for the 1.37 × 1.37 × 2.00 mm3 dose grid.

Detector
1
2
3
4

Planned
D/F (cGy)
311.7
306.5
286.5
258.0

Measured
D/F (cGy)
325.9
331.5
326.2
282.0

Measured
D/F
Uncertainty (cGy)
12.7
18.9
13.3
12.2

% Difference
4.572
8.161
13.86
9.293

Table A.16
TM
Comparison between TomoTherapy R TPS data and measured dose using four MOSkin
detectors with the solid probe at θ = 0◦ for the 1.37 × 1.37 × 1.00 mm3 dose grid. Fiducial
markers were attached to the probe.

Detector
1
2
3
4

Planned
D/F (cGy)
215.8
206.7
185.3
179.0

Measured
D/F (cGy)
192.3
193.0
180.1
161.1

Measured
D/F
Uncertainty (cGy)
5.8
3.9
7.5
6.3

% Difference
-10.91
-6.625
-2.823
-10.02

Table A.17
TM
Comparison between TomoTherapy R TPS data and measured dose using four MOSkin
detectors with the solid probe at θ = 90◦ for the 1.37 × 1.37 × 1.00 mm3 dose grid. Fiducial
markers were attached to the probe.
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Tabulated TPS and Measured Data

Detector
1
2
3
4

Planned
D/F (cGy)
181.0
166.5
139.0
139.3

Measured
D/F (cGy)
165.0
158.6
136.6
121.5

Measured
D/F
Uncertainty (cGy)
2.8
3.7
2.6
1.6

% Difference
-8.847
-4.775
-1.741
-12.82

Table A.18
TM
Comparison between TomoTherapy R TPS data and measured dose using four MOSkin
detectors with the solid probe at θ = 180◦ for the 1.37 × 1.37 × 1.00 mm3 dose grid. Fiducial
markers were attached to the probe.

Detector
1
2
3
4

Planned
D/F (cGy)
311.7
306.5
286.5
257.8

Measured
D/F (cGy)
298.5
306.0
294.5
271.4

Measured
D/F
Uncertainty (cGy)
10.9
5.1
2.3
7.1

% Difference
-4.222
-0.1602
2.777
5.268

Table A.19
Comparison between TomoTherapy R TPS data and measured dose using four dual
TM
MOSkin
detectors with the solid probe at θ = 0◦ for the 1.37 × 1.37 × 1.00 mm3 dose
grid.

Detector
1
2
3
4

Planned
D/F (cGy)
215.0
196.0
185.3
174.5

Measured
D/F (cGy)
189.5
196.8
178.9
162.3

Measured
D/F
Uncertainty (cGy)
7.1
9.2
5.4
3.2

% Difference
-11.88
0.4190
-3.462
-6.994

Table A.20
TM
Comparison between TomoTherapy TPS data and measured dose using four dual MOSkin
detectors with the solid probe at θ = 90◦ for the 1.37 × 1.37 × 1.00 mm3 dose grid.
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Tabulated TPS and Measured Data

Detector
1
2
3
4

Planned
D/F (cGy)
181.0
168.0
136.3
139.7

Measured
D/F (cGy)
165.2
165.7
137.6
128.2

Measured
D/F
Uncertainty (cGy)
12.9
1.5
2.3
2.0

% Difference
-8.729
-1.345
-0.9038
-8.180

Table A.21
TM
Comparison between TomoTherapy TPS data and measured dose using four dual MOSkin
detectors with the solid probe at θ = 180◦ for the 1.37 × 1.37 × 1.00 mm3 dose grid.

